| Ident. | Authors (with country if any) | Title |
|---|
| 000006 |
Kathryn N. Parkinson [Royaume-Uni] ; Heather O. Dickinson [Royaume-Uni] ; Catherine Arnaud [France] ; Alan Lyons [Irlande (pays)] ; Allan Colver [Royaume-Uni] ; Eva Beckung ; Jackie Parkes ; Jérôme Fauconnier ; Alan Lyons ; Susan Michelsen ; Marco Marcelli ; Catherine Arnaud ; Ute Thyen ; Marion Rapp | Pain in young people aged 13 to 17 years with cerebral palsy: cross-sectional, multicentre European study |
| 000010 |
Renato Puppi Munhoz [Brésil] ; Hélio A. Teive [Brésil] ; Hariklia Eleftherohorinou [Royaume-Uni] ; Lachlan J. Coin [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Laura Silveira-Moriyama [Royaume-Uni, Brésil] | Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson's disease |
| 000011 |
Keyoumars Ashkan [Royaume-Uni] ; Paul Shotbolt [Royaume-Uni] ; Anthony S. David [Royaume-Uni] ; Michael Samuel [Royaume-Uni] | Deep brain stimulation: a return journey from psychiatry to neurology |
| 000012 |
Mojtaba Zarei [Royaume-Uni, Iran] ; Naroa Ibarretxe-Bilbao [Espagne] ; Yaroslau Compta [Espagne] ; Morgan Hough [Royaume-Uni] ; Carme Junque [Espagne] ; Nuria Bargallo [Espagne] ; Eduardo Tolosa [Espagne] ; Maria Jose Martí [Espagne] | Cortical thinning is associated with disease stages and dementia in Parkinson's disease |
| 000016 |
D C Consonni [Italie] ; Straif [France] ; Symons [États-Unis] ; Tomenson [Royaume-Uni] ; Amelsvoort Van [Pays-Bas] ; Sleeuwenhoek [Royaume-Uni] ; Cherrie [Royaume-Uni] ; Bonetti [Italie] ; Colombo [Italie] ; Farrar [Royaume-Uni] ; Carugno [Italie] ; Bertazzi [Italie] | 284 Cancer risk among tetrafluoroethylene (TFE) synthesis and polymerisation workers |
| 000022 |
Pv Dissanayake [Royaume-Uni] ; R. Wasala [Royaume-Uni] | Wolff-parkinson-white syndrome diagnosed following binge drinking associated arrhythmia |
| 000029 |
Claire L. Tomlinson [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Charmaine Meek [Royaume-Uni] ; Clare P. Herd [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Rebecca Stowe [Royaume-Uni] ; Laila Shah [Royaume-Uni] ; Catherine Sackley [Royaume-Uni] ; Katherine H O. Deane [Royaume-Uni] ; Keith Wheatley [Royaume-Uni] ; Natalie Ives [Royaume-Uni] | Physiotherapy intervention in Parkinson’s disease: systematic review and meta-analysis |
| 000039 |
Andreas R. Kupsch [Allemagne] ; Nin Bajaj [Royaume-Uni] ; Frederick Weiland [États-Unis] ; Antonio Tartaglione [Italie] ; Susanne Klutmann [Allemagne] ; Melanie Buitendyk [Canada] ; Paul Sherwin [États-Unis] ; Ann Tate [États-Unis] ; Igor D. Grachev [États-Unis] | Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study |
| 000046 |
Matthew B. Davidson [Royaume-Uni] ; David J M. Mcghee [Royaume-Uni] ; Carl E. Counsell [Royaume-Uni] | Comparison of patient rated treatment response with measured improvement in Parkinson's disease |
| 000048 |
Manu Sharma ; John P A. Ioannidis [États-Unis] ; Jan O. Aasly [Norvège] ; Grazia Annesi [Italie] ; Alexis Brice [France] ; Lars Bertram [Allemagne] ; Maria Bozi [Grèce] ; Maria Barcikowska [Pologne] ; David Crosiers [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Maurizio F. Facheris ; Matthew Farrer [Canada] ; Gaetan Garraux ; Suzana Gispert [Allemagne] ; Georg Auburger ; Carles Vilari O-Güell [Canada] ; Georgios M. Hadjigeorgiou [Grèce] ; Andrew A. Hicks ; Nobutaka Hattori [Japon] ; Beom S. Jeon [Corée du Sud] ; Zygmunt Jamrozik [Pologne] ; Anna Krygowska-Wajs [Pologne] ; Suzanne Lesage [France] ; Christina M. Lill [Grèce, Allemagne] ; Juei-Jueng Lin [Taïwan] ; Timothy Lynch [Irlande (pays)] ; Peter Lichtner [Allemagne] ; Anthony E. Lang [Canada] ; Cecile Libioulle [Canada] ; Miho Murata [Japon] ; Vincent Mok [Hong Kong] ; Barbara Jasinska-Myga [Pologne] ; George D. Mellick [Australie] ; Karen E. Morrison [Royaume-Uni] ; Thomas Meitnger [Allemagne] ; Alexander Zimprich [Autriche] ; Grzegorz Opala [Allemagne] ; Peter P. Pramstaller ; Irene Pichler ; Sung Sup Park [Allemagne] ; Aldo Quattrone [Italie] ; Ekaterina Rogaeva [Canada] ; Owen A. Ross [États-Unis] ; Leonidas Stefanis [Grèce] ; Joanne D. Stockton [Royaume-Uni] ; Wataru Satake [Japon] ; Peter A. Silburn [Australie] ; Tim M. Strom [Allemagne, Canada] ; Jessie Theuns [Belgique] ; Eng- King Tan [Singapour] ; Tatsushi Toda [Japon] ; Hiroyuki Tomiyama [Japon] ; Ryan J. Uitti [États-Unis] ; Christine Van Broeckhoven [Belgique] ; Karin Wirdefeldt ; Zbigniew Wszolek [États-Unis] ; Georgia Xiromerisiou [Grèce] ; Harumi S. Yomono [Japon] ; Kuo-Chu Yueh [Taïwan] ; Yi Zhao ; Thomas Gasser ; Demetrius Maraganore [États-Unis] ; Rejko Krüger | A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants |
| 000050 |
Jose Bras [Royaume-Uni] ; Rita Guerreiro [Royaume-Uni] ; John Hardy [Royaume-Uni] | Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease |
| 000057 |
Steve Arnold [Royaume-Uni] ; Georgios Pampalakis [Grèce] ; Kalliopi Kantiotou [Grèce] ; Dilson Silva [Brésil] ; Celia Cortez [Brésil] ; Sotiris Missailidis [Royaume-Uni] ; Georgia Sotiropoulou [Grèce] | One round of SELEX for the generation of DNA aptamers directed against KLK6 |
| 000061 |
Chong Gao [République populaire de Chine] ; Christian Hölscher [Royaume-Uni] ; Yueze Liu [République populaire de Chine] ; Lin Li [République populaire de Chine] | GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease |
| 000062 |
Anne Corbett [Royaume-Uni] ; James Pickett [Royaume-Uni] ; Alistair Burns [Royaume-Uni] ; Jonathan Corcoran [Royaume-Uni] ; Stephen B. Dunnett [Royaume-Uni] ; Paul Edison [Royaume-Uni] ; Jim J. Hagan [Royaume-Uni] ; Clive Holmes [Royaume-Uni] ; Emma Jones [Royaume-Uni] ; Cornelius Katona [Royaume-Uni] ; Ian Kearns [Royaume-Uni] ; Patrick Kehoe [Royaume-Uni] ; Amrit Mudher [Royaume-Uni] ; Anthony Passmore [Royaume-Uni] ; Nicola Shepherd [Royaume-Uni] ; Frank Walsh [Royaume-Uni] ; Clive Ballard [Royaume-Uni] | Drug repositioning for Alzheimer's disease |
| 000067 |
Zhijun Yao [République populaire de Chine] ; Bin Hu [République populaire de Chine, Royaume-Uni] ; Lina Zhao [République populaire de Chine] ; Chuanjiang Liang [République populaire de Chine] | Analysis of Gray Matter in AD Patients and MCI Subjects Based Voxel-Based Morphometry |
| 000071 |
Jonathan R. Evans [Royaume-Uni] ; Sarah L. Mason [Royaume-Uni] ; Caroline H. Williams-Gray [Royaume-Uni] ; Thomas Foltynie [Royaume-Uni] ; Carol Brayne [Royaume-Uni] ; Trevor W. Robbins [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] | The natural history of treated Parkinson's disease in an incident, community based cohort |
| 000076 |
T. Foltynie [Royaume-Uni] ; L. Zrinzo [Royaume-Uni] ; I. Martinez-Torres [Espagne] ; E. Tripoliti [Royaume-Uni] ; E. Petersen [États-Unis] ; E. Holl [Royaume-Uni, Autriche] ; I. Aviles-Olmos [Royaume-Uni] ; M. Jahanshahi [Royaume-Uni] ; M. Hariz [Royaume-Uni, Suède] ; P. Limousin [Royaume-Uni] | MRI-guided STN DBS in Parkinson's disease without microelectrode recording: efficacy and safety |
| 000087 |
Hayriye Cagnan [Royaume-Uni] ; Kevin Dolan [Pays-Bas] ; Xuan He [Pays-Bas] ; Maria Fiorella Contarino [Pays-Bas] ; Richard Schuurman [Pays-Bas] ; Pepijn Van Den Munckhof [Pays-Bas] ; Wytse J. Wadman [Pays-Bas] ; Lo Bour [Pays-Bas] ; Hubert C F. Martens [Pays-Bas] | Automatic subthalamic nucleus detection from microelectrode recordings based on noise level and neuronal activity |
| 000088 |
Christopher Wren [Royaume-Uni] ; Melanie Vogel [Allemagne] ; Stephen Lord [Royaume-Uni] ; Dominic Abrams [Royaume-Uni] ; John Bourke [Royaume-Uni] ; Philip Rees [Royaume-Uni] ; Eric Rosenthal [Royaume-Uni] | Accuracy of algorithms to predict accessory pathway location in children with Wolff–Parkinson–White syndrome |
| 000090 |
Yan Rolland [France] ; Marc Vérin [France] ; Christine A. Payan [France] ; Simon Duchesne [Canada] ; Eduard Kraft [Allemagne] ; Till K. Hauser [Allemagne] ; Josef Jarosz [Royaume-Uni] ; Neil Deasy [Royaume-Uni] ; Luc Defevbre [France] ; Christine Delmaire [France] ; Didier Dormont [France] ; Albert C. Ludolph [Allemagne] ; Gilbert Bensimon [France] ; P Nigel Leigh [Royaume-Uni, France] | A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: validity and reliability |
| 000093 |
Mari Carmen Portillo [Royaume-Uni] ; Sarah Cowley [Royaume-Uni] | Working the way up in neurological rehabilitation: the holistic approach of nursing care |
| 000095 |
Angelo Antonini [Italie] ; Pablo Martinez-Martin [Espagne] ; Ray K. Chaudhuri [Royaume-Uni] ; Marcelo Merello [Argentine] ; Robert Hauser [États-Unis] ; Regina Katzenschlager [Autriche] ; Per Odin [Allemagne] ; Mark Stacy [États-Unis] ; Fabrizio Stocchi [Italie] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Anette Schrag [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] | Wearing‐off scales in Parkinson's disease: Critique and recommendations |
| 000096 |
Neil K. Archibald [Royaume-Uni] ; Mike P. Clarke [Royaume-Uni] ; Urs P. Mosimann [Royaume-Uni, Suisse] ; David J. Burn [Royaume-Uni] | Visual symptoms in Parkinson's disease and Parkinson's disease dementia |
| 000106 |
Andrew King ; Satomi Maekawa ; Istvan Bodi ; Claire Troakes [Royaume-Uni] ; Safa Al-Sarraj | Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP‐43 proteinopathies but are only rarely additionally immunopositive for phosphorylation‐dependent TDP‐43 |
| 000109 |
Elina Tripoliti [Royaume-Uni] ; Laura Strong [Royaume-Uni] ; Freya Hickey [Royaume-Uni] ; Tom Foltynie [Royaume-Uni] ; Ludvic Zrinzo [Royaume-Uni] ; Joseph Candelario [Royaume-Uni] ; Marwan Hariz [Royaume-Uni] ; Patricia Limousin [Royaume-Uni] | Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease |
| 000112 |
Gabriella Constantinescu [Australie] ; Deborah Theodoros [Australie] ; Trevor Russell [Australie] ; Elizabeth Ward [Australie] ; Stephen Wilson [Australie] ; Richard Wootton [Royaume-Uni] | Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non‐inferiority trial |
| 000120 |
Ashley H. Spencer [Royaume-Uni] ; Hugh Rickards [Royaume-Uni] ; Alfonso Fasano [Italie] ; Andrea E. Cavanna [Royaume-Uni] | The prevalence and clinical characteristics of punding in Parkinson's disease |
| 000125 |
Alison Yarnall [Royaume-Uni] ; Lynn Rochester [Royaume-Uni] ; David J. Burn [Royaume-Uni] | The interplay of cholinergic function, attention, and falls in Parkinson's disease |
| 000126 |
Pablo Martinez-Martin [Espagne] ; Carmen Rodriguez-Blazquez [Espagne] ; Monica M. Kurtis [Espagne] ; K. Ray Chaudhuri [Royaume-Uni] | The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson's disease |
| 000135 |
Anne Pavy-Le Traon [France] ; Gerard Amarenco [France] ; Susanne Duerr [Autriche] ; Horacio Kaufmann [États-Unis] ; Heinz Lahrmann [Autriche] ; Stephanie R. Shaftman [États-Unis] ; François Tison [France] ; Gregor K. Wenning [Autriche] ; Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Anette Schrag [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Olivier Rascol [France] | The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension |
| 000141 |
Lynn Rochester [Royaume-Uni] ; Katherine Baker [Royaume-Uni] ; Alice Nieuwboer [Belgique] ; David Burn [Royaume-Uni] | Targeting dopa‐sensitive and dopa‐resistant gait dysfunction in Parkinson's disease: Selective responses to internal and external cues |
| 000144 |
Nick Miller [Royaume-Uni] ; Emma Noble [Royaume-Uni] ; Diana Jones [Royaume-Uni] ; Katherine H. O. Deane [Royaume-Uni] ; Catherine Gibb [Royaume-Uni] | Survey of speech and language therapy provision for people with Parkinson's disease in the United Kingdom: patients' and carers' perspectives |
| 000155 |
Carl E. Clarke [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Caroline Rick [Royaume-Uni] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni] | Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? |
| 000164 |
Claudia Trenkwalder [Allemagne] ; Bryan Kies [Afrique du Sud] ; Monika Rudzinska [Pologne] ; Jennifer Fine [Afrique du Sud] ; Janos Nikl [Hongrie] ; Krystyna Honczarenko [Pologne] ; Peter Dioszeghy [Hongrie] ; Dennis Hill [États-Unis] ; Tim Anderson [Nouvelle-Zélande] ; Vilho Myllyla [Finlande] ; Jan Kassubek [Allemagne] ; Malcolm Steiger [Royaume-Uni] ; Marco Zucconi [Italie] ; Eduardo Tolosa [Espagne] ; Werner Poewe [Autriche] ; Erwin Surmann [Allemagne] ; John Whitesides [États-Unis] ; Babak Boroojerdi [Allemagne] ; Kallol Ray Chaudhuri [Royaume-Uni] ; the RECOVER Study Group | Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER) |
| 000177 |
M. Duleeka W. Knipe [Royaume-Uni] ; Mirdhu M. Wickremaratchi [Royaume-Uni] ; Emma Wyatt-Haines [Royaume-Uni] ; Huw R. Morris [Royaume-Uni] ; Yoav Ben-Shlomo [Royaume-Uni] | Quality of life in young‐ compared with late‐onset Parkinson's disease |
| 000184 |
Wassilios G. Meissner [France] ; Mark Frasier [États-Unis] ; Thomas Gasser [Allemagne] ; Christopher G. Goetz [États-Unis] ; Andres Lozano [Canada] ; Paola Piccini [Royaume-Uni] ; José A. Obeso [Espagne] ; Olivier Rascol [France] ; Anthony Schapira [Royaume-Uni] ; Valerie Voon [Royaume-Uni] ; David M. Weiner [États-Unis] ; François Tison [France] ; Erwan Bezard [France] | Priorities in Parkinson's disease research |
| 000193 |
Andrew Chan [Allemagne, Espagne] ; Munir Pirmohamed [Royaume-Uni] ; Manuel Comabella [Espagne] | Pharmacogenomics in neurology: Current state and future steps |
| 000197 |
Atbin Djamshidian [Royaume-Uni] ; Francisco Cardoso [Brésil] ; Donald Grosset [Royaume-Uni] ; Henrietta Bowden-Jones [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Pathological gambling in Parkinson's disease—a review of the literature |
| 000199 |
Hans-Gert Bernstein ; Mary Johnson ; Robert H. Perry ; Fiona E. N. Lebeau [Royaume-Uni] ; Henrik Dobrowolny ; Bernhard Bogerts ; Elaine K. Perry | Partial loss of parvalbumin‐containing hippocampal interneurons in dementia with Lewy bodies |
| 000202 |
Daniel Weintraub [États-Unis] ; David J. Burn [Royaume-Uni] | Parkinson's disease: The quintessential neuropsychiatric disorder |
| 000206 |
Claudia Trenkwalder [Allemagne] ; Ralf Kohnen [États-Unis, Allemagne] ; Birgit Högl [Autriche] ; Vinod Metta [Royaume-Uni] ; Friederike Sixel-Döring [Allemagne] ; Birgit Frauscher [Autriche] ; Julia Hülsmann [États-Unis, Allemagne] ; Pablo Martinez-Martin [Espagne] ; Kallol Ray Chaudhuri [Royaume-Uni] | Parkinson's disease sleep scale—validation of the revised version PDSS‐2 |
| 000207 |
Michael J. Devine [Royaume-Uni] ; Katrina Gwinn [États-Unis] ; Andrew Singleton [États-Unis] ; John Hardy [Royaume-Uni] | Parkinson's disease and α‐synuclein expression |
| 000213 |
Fabrizio Stocchi [Italie] ; Luigi Giorgi [Royaume-Uni] ; Brian Hunter [Royaume-Uni] ; Anthony Hv Schapira [Royaume-Uni] | PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease |
| 000215 |
Harriet Quigley [Royaume-Uni] ; Sean J. Colloby [Royaume-Uni] ; John T. O'Brien [Royaume-Uni] | PET imaging of brain amyloid in dementia: a review |
| 000232 |
Nick Miller [Royaume-Uni] ; Katherine H. O. Deane [Royaume-Uni] ; Diana Jones [Royaume-Uni] ; Emma Noble [Royaume-Uni] ; Catherine Gibb [Royaume-Uni] | National survey of speech and language therapy provision for people with Parkinson's disease in the United Kingdom: therapists’ practices |
| 000235 |
Peter Arthur-Farraj [Royaume-Uni] ; Katharina Wanek [Royaume-Uni] ; Janina Hantke [Royaume-Uni] ; Catherine M. Davis [États-Unis] ; Anuj Jayakar ; David B. Parkinson [Royaume-Uni] ; Rhona Mirsky [Royaume-Uni] ; Kristján R. Jessen [Royaume-Uni] | Mouse schwann cells need both NRG1 and cyclic AMP to myelinate |
| 000242 |
Julius Huebl [Allemagne] ; Thomas Schoenecker [Allemagne] ; Sandy Siegert [Allemagne] ; Christof Brücke [Allemagne] ; Gerd-Helge Schneider [Allemagne] ; Andreas Kupsch [Allemagne] ; Kielan Yarrow [Royaume-Uni] ; Andrea A. Kühn [Allemagne] | Modulation of subthalamic alpha activity to emotional stimuli correlates with depressive symptoms in Parkinson's disease |
| 000247 |
A. Jon Stoessl [Canada] ; David J. Brooks [Royaume-Uni] ; David Eidelberg [États-Unis] | Milestones in neuroimaging |
| 000249 |
Daniela Berg [Allemagne] ; Jonathan D. Steinberger [États-Unis] ; C. Warren Olanow [États-Unis] ; Thomas P. Naidich [États-Unis] ; Tarek A. Yousry [Royaume-Uni] | Milestones in magnetic resonance imaging and transcranial sonography of movement disorders |
| 000251 |
Mark Hallett [États-Unis, Royaume-Uni] ; John Rothwell [Royaume-Uni] | Milestones in clinical neurophysiology |
| 000253 |
Glenda Halliday [Australie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Matthew Stern [États-Unis] | Milestones in Parkinson's disease—Clinical and pathologic features |
| 000255 |
Thomas Gasser [Allemagne] ; John Hardy [Royaume-Uni] ; Yoshikuni Mizuno [Japon] | Milestones in PD genetics |
| 000260 |
Rebecca Stowe [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Kelly Handley [Royaume-Uni] ; Alexandra Furmston [Royaume-Uni] ; Katherine Deane [Royaume-Uni] ; J. J. Van Hilten [Pays-Bas] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni] | Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease |
| 000265 |
James A. Miller [États-Unis] ; Briana R. Trout [États-Unis] ; Kelly A. Sullivan [États-Unis] ; Russell A. Bialecki [États-Unis] ; Ruth A. Roberts [Royaume-Uni] ; Ronald B. Tjalkens [États-Unis] | Low‐dose 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor‐κB reporter mice prior to loss of dopaminergic neurons |
| 000274 |
S. Sharma [Royaume-Uni] ; R. Bandopadhyay ; T. Lashley ; A. E. M. Renton [Royaume-Uni] ; A. E. Kingsbury ; R. Kumaran ; C. Kallis ; C. Vilari O-Güell ; S. S. O'Sullivan ; Andrew Lees (neurologue) [Royaume-Uni] ; T. Revesz ; N. W. Wood ; J. L. Holton | LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study |
| 000278 |
Charlotte M. Wright [Royaume-Uni] ; Kirsty Cameron [Royaume-Uni] ; Maria Tsiaka [Royaume-Uni] ; Kathryn N. Parkinson [Royaume-Uni] | Is baby‐led weaning feasible? When do babies first reach out for and eat finger foods? |
| 000284 |
Maria Papathanou [Suède] ; Sarah Rose [Royaume-Uni] ; Andrew Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni] | Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats |
| 000292 |
Valerie Voon [Royaume-Uni] ; Mandy Sohr [Allemagne] ; Anthony E. Lang [Canada] ; Marc N. Potenza [États-Unis] ; Andrew D. Siderowf [États-Unis] ; Jacqueline Whetteckey [États-Unis] ; Daniel Weintraub [États-Unis] ; Glen R. Wunderlich [Canada] ; Mark Stacy [États-Unis] | Impulse control disorders in parkinson disease: A multicenter case–control study |
| 000293 |
D. Okai [Royaume-Uni] ; M. Samuel ; S. Askey-Jones [Royaume-Uni] ; A. S. David [Royaume-Uni] ; R. G. Brown [Royaume-Uni] | Impulse control disorders and dopamine dysregulation in Parkinson’s disease: a broader conceptual framework |
| 000302 |
Pablo Martinez-Martin [Espagne] ; Martine Jeukens-Visser [Pays-Bas] ; Kelly E. Lyons [États-Unis] ; C. Rodriguez-Blazquez [Espagne] ; Caroline Selai [Royaume-Uni] ; Andrew Siderowf [États-Unis] ; Mickie Welsh [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] ; Anette Schrag [Royaume-Uni] | Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations |
| 000309 |
Omar S. Mian [Royaume-Uni] ; Susanne A. Schneider [Royaume-Uni, Allemagne] ; Petra Schwingenschuh [Royaume-Uni, Autriche] ; Kailash P. Bhatia [Royaume-Uni] ; Brian L. Day [Royaume-Uni] | Gait in SWEDDs patients: Comparison with Parkinson's disease patients and healthy controls |
| 000311 |
Tessel Boertien [Royaume-Uni, Pays-Bas] ; Ludvic Zrinzo [Royaume-Uni] ; Joshua Kahan [Royaume-Uni] ; Marjan Jahanshahi [Royaume-Uni] ; Marwan Hariz [Royaume-Uni] ; Laura Mancini [Royaume-Uni] ; Patricia Limousin [Royaume-Uni] ; Thomas Foltynie [Royaume-Uni] | Functional imaging of subthalamic nucleus deep brain stimulation in Parkinson's disease |
| 000318 |
Peter Jenner [Royaume-Uni] ; J. William Langston [États-Unis] | Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline |
| 000324 |
Anthony H. Schapira [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Etiology and pathogenesis of Parkinson's disease |
| 000326 |
Maria Davies ; Elizabeth M. Paice ; Sian B. Jones ; Sam Leary [Royaume-Uni] ; Andrew R. Curtis ; Nicola X. West | Efficacy of desensitizing dentifrices to occlude dentinal tubules |
| 000343 |
Friederike Fritze [Norvège] ; Uwe Ehrt [Norvège] ; Hogne S Nnesyn [Norvège] ; Martin Kurz [Norvège] ; Tibor Hortobágyi [Royaume-Uni] ; Sabine Piepenstock Nore [Norvège] ; Clive Ballard [Royaume-Uni] ; Dag Aarsland [Norvège] | Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features |
| 000345 |
Helen Ling [Royaume-Uni] ; Mark Braschinsky [Estonie] ; Pille Taba [Estonie] ; Siiri-Merike Lüüs [Estonie] ; Karen Doherty [Royaume-Uni] ; Anna Hotter [Autriche] ; Werner Poewe [Autriche] ; Andrew Lees (neurologue) [Royaume-Uni] | Decades of delayed diagnosis in 4 levodopa‐responsive young‐onset monogenetic parkinsonism patients |
| 000346 |
J. C. Dachsel [États-Unis] ; C. Wider [États-Unis, Suisse] ; C. Vilari O-Güell [États-Unis] ; J. O. Aasly [Norvège] ; A. Rajput [Canada] ; A. H. Rajput [Canada] ; T. Lynch [Irlande (pays)] ; D. Craig [Royaume-Uni] ; A. Krygowska-Wajs [Pologne] ; B. Jasinska-Myga [États-Unis] ; G. Opala ; M. Barcikowska [Pologne] ; K. Czyzewski [Pologne] ; R. Wu [Taïwan] ; M. G. Heckman [États-Unis] ; R. J. Uitti [États-Unis] ; Z. K. Wszolek [États-Unis] ; M. J. Farrer [États-Unis] ; O. A. Ross [États-Unis] | Death‐associated protein kinase 1 variation and Parkinson’s disease |
| 000353 |
Carmen Agustín-Pav N [Royaume-Uni] ; John Parkinson [Royaume-Uni] ; Mei-See Man [Royaume-Uni] ; Angela C. Roberts [Royaume-Uni] | Contribution of the amygdala, but not orbitofrontal or medial prefrontal cortices, to the expression of flavour preferences in marmoset monkeys |
| 000363 |
Stephanie M. Van Rooden [Pays-Bas] ; Fabrice Colas [Pays-Bas] ; Pablo Martínez-Martín [Espagne] ; Martine Visser [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Ray K. Chaudhuri [Royaume-Uni] ; Joost N. Kok [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas] | Clinical subtypes of Parkinson's disease |
| 000370 |
A. H. V. Schapira [Royaume-Uni] | Challenges to the development of disease‐modifying therapies in Parkinson’s disease |
| 000389 |
Viduth K. Chaugule [Royaume-Uni] ; Lynn Burchell [Royaume-Uni] ; Kathryn R. Barber [Canada] ; Ateesh Sidhu [Royaume-Uni] ; Simon J. Leslie [Royaume-Uni] ; Gary S. Shaw [Canada] ; Helen Walden [Royaume-Uni] | Autoregulation of Parkin activity through its ubiquitin‐like domain |
| 000407 |
Daniela Berg [Allemagne] ; Jana Godau [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Karla Eggert [Allemagne] ; Iiona Csoti [Allemagne] ; Alexander Storch [Allemagne] ; Heiko Huber [Allemagne] ; Monica Morelli-Canelo [Allemagne] ; Maria Stamelou [Allemagne] ; Vincent Ries [Allemagne] ; Martin Wolz [Allemagne] ; Christine Schneider [Allemagne] ; Thérèse Di Paolo [Canada] ; Fabrizio Gasparini [Suisse] ; Sam Hariry [Suisse] ; Marc Vandemeulebroecke [Suisse] ; Walid Abi-Saab [Suisse] ; Katy Cooke [Royaume-Uni] ; Donald Johns [Suisse] ; Baltazar Gomez-Mancilla [Suisse] | AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials |
| 000419 |
A. E. Vanhaesebrouck [Royaume-Uni] ; G. D. Shelton [États-Unis] ; L. Garosi [Royaume-Uni] ; T. R. Harcourt-Brown [Royaume-Uni] ; J. Couturier [Royaume-Uni] ; S. Behr [Royaume-Uni] ; R. J. Harvey [Royaume-Uni] ; N. D. Jeffery [Royaume-Uni, États-Unis] ; K. Matiasek [Allemagne] ; W. F. Blakemore [Royaume-Uni] ; N. Granger [Royaume-Uni] | A Novel Movement Disorder in Related Male Labrador Retrievers Characterized by Extreme Generalized Muscular Stiffness |
| 000424 |
Ainrs Stepens [Lettonie] ; Charlotte Jane Stagg [Royaume-Uni] ; Ardis Platkjis [Lettonie] ; Marie-Hlne Boudrias [Royaume-Uni] ; Heidi Johansen-Berg [Royaume-Uni] ; Michael Donaghy [Royaume-Uni] | White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome |
| 000425 |
Charlotte M. Wright [Royaume-Uni] ; David H. Stone [Royaume-Uni] ; Kathryn N. Parkinson [Royaume-Uni] | Undernutrition in British Haredi infants within the Gateshead Millennium Cohort Study |
| 000426 |
Peter Hobson [Royaume-Uni] ; Jolyon Meara [Royaume-Uni] ; Lianna Ishihara-Paul [Royaume-Uni] | The estimated life expectancy in a community cohort of Parkinson's disease patients with and without dementia, compared with the UK population |
| 000436 |
Pablo Garcia-Reitbck [Royaume-Uni] ; Oleg Anichtchik [Royaume-Uni] ; Arianna Bellucci [Italie] ; Mariangela Iovino [Royaume-Uni] ; Chiara Ballini [Italie] ; Elena Fineberg [Royaume-Uni] ; Bernardino Ghetti [États-Unis] ; Laura Della Corte [Italie] ; Pierfranco Spano [Italie] ; George K. Tofaris [Royaume-Uni] ; Michel Goedert [Royaume-Uni] ; Maria Grazia Spillantini [Royaume-Uni] | SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinsons disease |
| 000440 |
Maria Stamelou [Allemagne] ; Rohan De Silva [Royaume-Uni] ; Oscar Arias-Carrin [Allemagne] ; Evangelia Boura [Allemagne] ; Matthias Hllerhage [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Ulrich Mller [Allemagne] ; Gnter U. Hglinger [Allemagne] | Rational therapeutic approaches to progressive supranuclear palsy |
| 000444 |
Mark R. Cookson ; Oliver Bandmann [Royaume-Uni] | Parkinson's disease: insights from pathways |
| 000453 |
Matthew E. Gegg [Royaume-Uni] ; J. Mark Cooper ; Kai-Yin Chau ; Manuel Rojo ; Anthony H. V. Schapira ; Jan-Willem Taanman | Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy |
| 000463 |
Bhomraj Thanvi [Royaume-Uni] ; Sean D. Treadwell [Royaume-Uni] | Freezing of gait in older people: associated conditions, clinical aspects, assessment and treatment |
| 000465 |
Nicola Pavese [Royaume-Uni] ; Vinod Metta [Royaume-Uni] ; Subrata K. Bose [Royaume-Uni] ; Kallol Ray Chaudhuri [Royaume-Uni] ; David J. Brooks [Royaume-Uni] | Fatigue in Parkinsons disease is linked to striatal and limbic serotonergic dysfunction |
| 000473 |
Wesley Thevathasan [Royaume-Uni] ; Ralph Gregory [Royaume-Uni] | Deep brain stimulation for movement disorders |
| 000477 |
Richard G. Brown [Royaume-Uni] ; Lucette Lacomblez [France] ; Bernard G. Landwehrmeyer [Allemagne] ; Thomas Bak [Royaume-Uni] ; Ingo Uttner [Allemagne] ; Bruno Dubois [France] ; Yves Agid [France] ; Albert Ludolph [Allemagne] ; Gilbert Bensimon [France] ; Christine Payan [France] ; Nigel P. Leigh [Royaume-Uni] | Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy |
| 000481 |
Guido Alves [Norvège] ; Kolbj Rn Br Nnick [Norvège] ; Dag Aarsland [Norvège] ; Kaj Blennow [Suède] ; Henrik Zetterberg [Suède] ; Clive Ballard [Royaume-Uni] ; Martin Wilhelm Kurz [Norvège] ; Ulf Andreasson [Suède] ; Ole-Bj Rn Tysnes [Norvège] ; Jan Petter Larsen [Norvège] ; Ezra Mulugeta [Norvège, Royaume-Uni] | CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study |
| 000482 |
John V. Hindle [Royaume-Uni] | Ageing, neurodegeneration and Parkinsons disease |
| 000483 |
Nin P S. Bajaj [Royaume-Uni] ; Vamsi Gontu [Royaume-Uni] ; James Birchall [Royaume-Uni] ; James Patterson [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study |
| 000485 |
Kenya Nishioka [États-Unis] ; Mounir Kefi [Tunisie] ; Barbara Jasinska-Myga [États-Unis, Pologne] ; Christian Wider [États-Unis] ; Carles Vilari O-Güell [États-Unis] ; Owen A. Ross [États-Unis] ; Michael G. Heckman [États-Unis] ; Lefkos T. Middleton [Royaume-Uni] ; Lianna Ishihara-Paul [Royaume-Uni] ; Rachel A. Gibson [Royaume-Uni] ; Rim Amouri [Tunisie] ; Samia Ben Yahmed [Tunisie] ; Samia Ben Sassi [Tunisie] ; Mourad Zouari [Tunisie] ; Ghada El Euch [Tunisie] ; Matthew J. Farrer [États-Unis] ; Faycal Hentati [Tunisie] | A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease |
| 000486 |
J. Deeb [Royaume-Uni] ; M. Shah [Royaume-Uni] ; N. Muhammed [Royaume-Uni] ; R. Gunasekera [Royaume-Uni] ; K. Gannon [Royaume-Uni] ; L. J. Findley [Royaume-Uni] ; C. H. Hawkes [Royaume-Uni] | A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinsons disease |
| 000490 |
David A. Gallagher [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Anette Schrag [Royaume-Uni] | What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? |
| 000495 |
Craig A. Heath [Royaume-Uni] ; Sarah A. Cooper [Royaume-Uni] ; Katy Murray [Royaume-Uni] ; Andrea Lowman [Royaume-Uni] ; Colm Henry [Irlande (pays)] ; Margaret A. Macleod [Royaume-Uni] ; Gillian E. Stewart [Royaume-Uni] ; Martin Zeidler [Royaume-Uni] ; Jan M. Mackenzie [Royaume-Uni] ; James W. Ironside [Royaume-Uni] ; David M. Summers [Royaume-Uni] ; Richard S. G. Knight [Royaume-Uni] ; Robert G. Will [Royaume-Uni] | Validation of diagnostic criteria for variant Creutzfeldt–Jakob disease |
| 000499 |
Benedikt Bader [Allemagne] ; Ruth H. Walker [États-Unis] ; Mathias Vogel [Allemagne] ; Mario Prosiegel [Allemagne] ; Jacqueline Mcintosh [Royaume-Uni] ; Adrian Danek [Allemagne] | Tongue protrusion and feeding dystonia: A hallmark of chorea‐acanthocytosis |
| 000508 |
G. K Gi [Royaume-Uni] ; K P Bhatia [Royaume-Uni] ; E. Tolosa [Espagne] | The role of DAT-SPECT in movement disorders |
| 000516 |
K. Ray Chaudhuri [Royaume-Uni] ; Cristina Prieto-Jurcynska [Espagne] ; Yogini Naidu [Royaume-Uni] ; Tanya Mitra [Royaume-Uni] ; Belen Frades-Payo [Espagne] ; Susanne Tluk [Royaume-Uni] ; Anne Ruessmann [Allemagne] ; Per Odin [Allemagne] ; Graeme Macphee [Royaume-Uni] ; Fabrizio Stocchi [Italie] ; William Ondo [États-Unis] ; Kapil Sethi [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Juan Carlos Martinez Castrillo [Espagne] ; Pablo Martinez-Martin [Espagne] | The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire |
| 000517 |
Kitty M. Suddick ; Simon Chambers [Royaume-Uni] | The lived experience of sleep disturbance in people with Parkinson’s disease |
| 000524 |
David J. Burn [Royaume-Uni] | The Treatment of Cognitive Impairment Associated with Parkinson's Disease |
| 000530 |
Carlo Colosimo [Italie] ; Pablo Martínez-Martín [Espagne] ; Giovanni Fabbrini [Italie] ; Robert A. Hauser [États-Unis] ; Marcelo Merello [Argentine] ; Janis Miyasaki [Canada] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni] ; Christopher G. Goetz [États-Unis] | Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations |
| 000532 |
Claire L. Tomlinson [Royaume-Uni] ; Rebecca Stowe [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Caroline Rick [Royaume-Uni] ; Richard Gray [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] | Systematic review of levodopa dose equivalency reporting in Parkinson's disease |
| 000533 |
J. S. K. Kauwe [États-Unis] ; S. Bertelsen [États-Unis] ; K. Mayo [États-Unis] ; C. Cruchaga [États-Unis] ; R. Abraham [Royaume-Uni] ; P. Hollingworth [Royaume-Uni] ; D. Harold [Royaume-Uni] ; M. J. Owen [Royaume-Uni] ; J. Williams [Royaume-Uni] ; S. Lovestone [Royaume-Uni] ; J. C. Morris [États-Unis] ; A. M. Goate [États-Unis] | Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease |
| 000538 |
Katharina Wulff [Royaume-Uni] ; Silvia Gatti [Suisse] ; Joseph G. Wettstein [Suisse] ; Russell G. Foster [Royaume-Uni] | Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease |
| 000548 |
Birgit Högl [Autriche] ; Isabelle Arnulf [France] ; Cynthia Comella [États-Unis] ; Joaquim Ferreira [Portugal] ; Alex Iranzo [Espagne] ; Barbara Tilley [États-Unis] ; Claudia Trenkwalder [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni] ; Christopher G. Goetz [États-Unis] | Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations |
| 000553 |
Atbin Djamshidian [Royaume-Uni, Autriche] ; Ashwani Jha [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Laura Silveira-Moriyama [Royaume-Uni] ; Clare Jacobson [Royaume-Uni] ; Peter Brown [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Bruno B. Averbeck [Royaume-Uni] | Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease |
| 000561 |
Hu Liang Low [Royaume-Uni] | Reply: The ‘plait sign’ of neurostimulator torsion |
| 000572 |
C. A. Guevara [Royaume-Uni] ; C. R. Blain [Royaume-Uni] ; D. Stahl [Royaume-Uni] ; D. J. Lythgoe [Royaume-Uni] ; P. N. Leigh [Royaume-Uni] ; G. J. Barker [Royaume-Uni] | Quantitative magnetic resonance spectroscopic imaging in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy |
| 000580 |
Giuseppe Limongelli [Royaume-Uni] ; Maite Tome-Esteban [Royaume-Uni] ; Charungthai Dejthevaporn [Royaume-Uni] ; Shamima Rahman [Royaume-Uni] ; Michael G. Hanna [Royaume-Uni] ; Perry M. Elliott [Royaume-Uni] | Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease |
| 000582 |
Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni] | Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets |
| 000598 |
Marios Politis [Royaume-Uni] ; Kit Wu [Royaume-Uni] ; Sophie Molloy [Royaume-Uni] ; Peter G. Bain [Royaume-Uni] ; K. Ray Chaudhuri [Royaume-Uni] ; Paola Piccini [Royaume-Uni] | Parkinson's disease symptoms: The patient's perspective |
| 000600 |
Laura E. Hughes [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] ; Adrian M. Owen [Royaume-Uni] ; James B. Rowe [Royaume-Uni] | Parkinson's disease and healthy aging: Independent and interacting effects on action selection |
| 000603 |
Louisa Clare Johnston [Royaume-Uni] ; Michael John Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Andrew Christopher Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni] | Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets |
| 000614 |
Naroa Ibarretxe-Bilbao [Espagne] ; Carme Junque [Espagne] ; Maria-Jose Marti [Espagne] ; Francesc Valldeoriola [Espagne] ; Pere Vendrell [Espagne] ; Nuria Bargallo [Espagne] ; Mojtaba Zarei [Royaume-Uni] ; Eduardo Tolosa [Espagne] | Olfactory impairment in Parkinson's disease and white matter abnormalities in central olfactory areas: A voxel‐based diffusion tensor imaging study |
| 000615 |
Laura Silveira-Moriyama [Royaume-Uni] ; Renato Pupi Munhoz [Brésil] ; Margarete De J. Carvalho [Brésil] ; Salmo Raskin [Brésil] ; Ekaterina Rogaeva [Canada] ; Patricia De C. Aguiar [Brésil] ; Rodrigo A. Bressan [Brésil] ; Andre C. Felicio [Brésil] ; Orlando G. P. Barsottini [Brésil] ; Luiz Augusto F. Andrade [Brésil] ; Hsin F. Chien [Brésil] ; Vincenzo Bonifati [Pays-Bas] ; Egberto R. Barbosa [Brésil] ; Helio A. Teive [Brésil] ; Andrew Lees (neurologue) [Royaume-Uni] | Olfactory heterogeneity in LRRK2 related Parkinsonism |
| 000643 |
Richard Dodel [Allemagne] ; Annika Spottke [Allemagne] ; Alexander Gerhard [Royaume-Uni] ; Alexander Reuss [Allemagne] ; Sylvia Reinecker [Allemagne] ; Nicole Schimke [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Friederike Sixel-Döring [Allemagne] ; Birgit Herting [Allemagne] ; Christoph Kamm [Allemagne] ; Thomas Gasser [Allemagne] ; Martin Sawires [Autriche] ; Felix Geser [Autriche] ; Martin Köllensperger [Autriche] ; Klaus Seppi [Autriche] ; Manja Kloss [Allemagne] ; Martin Krause [Allemagne] ; Christine Daniels [Allemagne] ; Günther Deuschl [Allemagne] ; Silke Böttger [Allemagne] ; Markus Naumann [Allemagne] ; Axel Lipp [Royaume-Uni] ; Doreen Gruber [Allemagne] ; Andreas Kupsch [Allemagne] ; Yansheng Du [États-Unis] ; Federico Turkheimer [Royaume-Uni] ; David J. Brooks [Royaume-Uni] ; Thomas Klockgether [Allemagne] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Carmen Schade-Brittinger [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Karla Eggert [Allemagne] | Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial) |
| 000649 |
Daniella Rylander [Suède] ; Martin Parent [Canada] ; Sean S. O'Sullivan [Royaume-Uni] ; Sandra Dovero [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Erwan Bezard [France] ; Laurent Descarries [Canada] ; M. Angela Cenci [Suède] | Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia |
| 000655 |
Elena Moro [Canada] ; Andres M. Lozano [Canada] ; Pierre Pollak [France] ; Yves Agid [France] ; Stig Rehncrona [Suède] ; Jens Volkmann [Allemagne] ; Jaime Kulisevsky [Espagne] ; Jose A. Obeso [Espagne] ; Alberto Albanese [Italie] ; Marwan I. Hariz [Royaume-Uni, Suède] ; Niall P. Quinn [Royaume-Uni] ; Jans D. Speelman [Pays-Bas] ; Alim-Louis Benabid [France] ; Valerie Fraix [France] ; Alexandre Mendes [France] ; Marie-Laure Welter [France] ; Jean-Luc Houeto [France] ; Philippe Cornu [France] ; Didier Dormont [France] ; Annalena L. Tornqvist [Suède] ; Ron Ekberg [Suède] ; Alfons Schnitzler [Allemagne] ; Lars Timmermann [Allemagne] ; Lars Wojtecki [Allemagne] ; Andres Gironell [Espagne] ; Maria C. Rodriguez-Oroz [Espagne] ; Jorge Guridi [Espagne] ; Anna R. Bentivoglio [Italie] ; Maria F. Contarino [Italie, Pays-Bas] ; Luigi Romito [Italie] ; Massimo Scerrati [Italie] ; Marc Janssens [Pays-Bas] ; Anthony E. Lang [Canada] | Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease |
| 000671 |
Annu Aggarwal [Inde] ; Susanne A. Schneider [Allemagne, Royaume-Uni] ; Henry Houlden [Royaume-Uni] ; Monty Silverdale [Royaume-Uni] ; Reema Paudel [Royaume-Uni] ; Coro Paisan-Ruiz [Royaume-Uni] ; Shrinivas Desai [Inde] ; Mihir Munshi [Inde] ; Darshana Sanghvi [Inde] ; John Hardy [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; Mohit Bhatt [Inde] | Indian‐subcontinent NBIA: Unusual phenotypes, novel PANK2 mutations, and undetermined genetic forms |
| 000681 |
Sean S. O'Sullivan [Royaume-Uni] ; Atbin Djamshidian [Royaume-Uni, Autriche] ; Zeshan Ahmed [Royaume-Uni] ; Andrew H. Evans [Australie] ; Andrew D. Lawrence [Royaume-Uni] ; Janice L. Holton [Royaume-Uni] ; Tamas Revesz [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Impulsive‐compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy |
| 000699 |
Peter Redgrave [Royaume-Uni] ; Manuel Rodriguez [Espagne] ; Yoland Smith [États-Unis] ; Maria C. Rodriguez-Oroz [Espagne] ; Stephane Lehericy [France] ; Hagai Bergman [Israël] ; Yves Agid [France] ; Mahlon R. Delong [États-Unis] ; Jose A. Obeso [Espagne] | Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease |
| 000714 |
Joseph H. Friedman [États-Unis] ; Guido Alves [Norvège] ; Peter Hagell [Suède] ; Johan Marinus [Pays-Bas] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni] | Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease |
| 000725 |
David J. Brooks [Royaume-Uni] | Examining Braak's hypothesis by imaging Parkinson's disease |
| 000755 |
Arjan W. Braam [Pays-Bas] ; Aartjan T. F. Beekman [Pays-Bas] ; Michael E. Dewey [Royaume-Uni] ; Philippe A. E. G. Delespaul [Pays-Bas] ; Manfred Fichter [Allemagne] ; Antonio Lobo [Espagne] ; Hallgrímur Magnússon [Islande] ; Karine Pérès [France] ; Friedel M. Reischies [Allemagne] ; Marc Roelands [Belgique] ; Pedro Saz [Espagne] ; Robert A. Schoevers [Pays-Bas] ; Ingmar Skoog [Suède] ; John R. M. Copeland [Royaume-Uni] | Depression and parkinsonism in older Europeans: results from the EURODEP concerted action |
| 000769 |
Pablo Arias [Espagne] ; Jamile Vivas [Espagne] ; Kenneth L. Grieve [Espagne, Royaume-Uni] ; Javier Cudeiro [Espagne] | Controlled trial on the effect of 10 days low‐frequency repetitive transcranial magnetic stimulation (rTMS) on motor signs in Parkinson's disease |
| 000770 |
Andrew H. Evans [Australie, Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Silke Appel Cresswell [Canada] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Lees (neurologue) [Royaume-Uni] | Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward |
| 000771 |
Barbara Jasinska-Myga [États-Unis, Pologne] ; Jennifer Kachergus [États-Unis] ; Carles Vilari O-Güell [États-Unis] ; Christian Wider [États-Unis] ; Alexandra I. Soto-Ortolaza [États-Unis] ; Mounir Kefi [Tunisie] ; Lefkos T. Middleton [Royaume-Uni] ; Lianna Ishihara-Paul [Royaume-Uni] ; Rachel A. Gibson [Royaume-Uni] ; Rim Amouri [Tunisie] ; Samia Ben Yahmed [Tunisie] ; Samia Ben Sassi [Tunisie] ; Mourad Zouari [Tunisie] ; Ghada El Euch [Tunisie] ; Owen A. Ross [États-Unis] ; Faycal Hentati [Tunisie] ; Matthew J. Farrer [États-Unis] | Comprehensive sequencing of the LRRK2 gene in patients with familial Parkinson's disease from North Africa |
| 000785 |
Esther Florin [Allemagne] ; Joachim Gross [Royaume-Uni] ; Christiane Reck [Allemagne] ; Mohammad Maarouf [Allemagne] ; Alfons Schnitzler [Allemagne] ; Volker Sturm [Allemagne] ; Gereon R. Fink [Allemagne] ; Lars Timmermann [Allemagne] | Causality between local field potentials of the subthalamic nucleus and electromyograms of forearm muscles in Parkinson’s disease |
| 000807 |
Gabriella Constantinescu [Australie] ; Deborah Theodoros [Australie] ; Trevor Russell [Australie] ; Elizabeth Ward [Australie] ; Stephen Wilson [Australie] ; Richard Wootton [Royaume-Uni] | Assessing disordered speech and voice in Parkinson's disease: a telerehabilitation application |
| 000809 |
Petra Schwingenschuh [Royaume-Uni, Autriche] ; Petra Katschnig [Royaume-Uni, Autriche] ; Ronald Saurugg [Autriche] ; Erwin Ott [Autriche] ; Kailash P. Bhatia [Royaume-Uni] | Artistic profession: A potential risk factor for dopamine dysregulation syndrome in Parkinson's disease? |
| 000821 |
Daniel Weintraub [États-Unis] ; Mandy Sohr [Allemagne] ; Marc N. Potenza [États-Unis] ; Andrew D. Siderowf [États-Unis] ; Mark Stacy [États-Unis] ; Valerie Voon [Royaume-Uni] ; Jacqueline Whetteckey [États-Unis] ; Glen R. Wunderlich [Canada] ; Anthony E. Lang [Canada] | Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study |
| 000822 |
Gerassimos E. Voutsinas [Grèce] ; Eleana F. Stavrou [Grèce] ; Gerassimos Karousos [Grèce] ; Aggeliki Dasoula [Grèce] ; Adamantia Papachatzopoulou [Grèce] ; Maria Syrrou [Grèce] ; Annemieke J. M. H. Verkerk [Pays-Bas] ; Peter Van Der Spek [Pays-Bas] ; George P. Patrinos [Pays-Bas, Grèce] ; Reinhard Stöger [États-Unis, Royaume-Uni] ; Aglaia Athanassiadou [Grèce] | Allelic imbalance of expression and epigenetic regulation within the alpha‐synuclein wild‐type and p.Ala53Thr alleles in Parkinson disease |
| 000841 |
Barry J. Snow [Nouvelle-Zélande] ; Fiona L. Rolfe [Nouvelle-Zélande] ; Michelle M. Lockhart [Nouvelle-Zélande] ; Christopher M. Frampton [Nouvelle-Zélande] ; John D. O'Sullivan [Australie] ; Victor Fung [Australie] ; Robin A. J. Smith [Nouvelle-Zélande] ; Michael P. Murphy [Royaume-Uni] ; Kenneth M. Taylor [Nouvelle-Zélande] | A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease |
| 000844 |
Anette Schrag [Royaume-Uni] ; Shamira Sheikh [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Caroline Selai [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Irene Litvan [États-Unis] ; Anthony E. Lang [Canada] ; James H. Bower [États-Unis] ; David J. Burn [Royaume-Uni] ; Philip Low [États-Unis] ; Marjan Jahanshahi [Royaume-Uni] | A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy |
| 000849 |
Rakkrit Duangsoithong [Royaume-Uni] ; Terry Windeatt [Royaume-Uni] | Relevance and Redundancy Analysis for Ensemble Classifiers |
| 000850 |
Uwe Ehrt [Norvège] ; Karl Broich [Allemagne] ; Jan Petter Larsen [Norvège] ; Clive Ballard [Royaume-Uni] ; Dag Aarsland [Norvège] | Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study |
| 000851 |
Neil K. Archibald [Royaume-Uni] ; Michael P. Clarke [Royaume-Uni] ; Urs P. Mosimann [Royaume-Uni] ; David J. Burn [Royaume-Uni] | The retina in Parkinson's disease |
| 000853 |
Caroline H. Williams-Gray [Royaume-Uni] ; Jonathan R. Evans [Royaume-Uni] ; An Goris [Royaume-Uni, Belgique] ; Thomas Foltynie [Royaume-Uni] ; Maria Ban [Royaume-Uni] ; Trevor W. Robbins [Royaume-Uni] ; Carol Brayne [Royaume-Uni] ; Bhaskar S. Kolachana [États-Unis] ; Daniel R. Weinberger [États-Unis] ; Stephen J. Sawcer [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] | The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort |
| 000864 |
K. Wu [Royaume-Uni] ; M. Politis [Royaume-Uni] ; P. Piccini [Royaume-Uni] | Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management |
| 000869 |
Rosa M. Sancho [Royaume-Uni] ; Bernard M. H. Law [Royaume-Uni] ; Kirsten Harvey [Royaume-Uni] | Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways |
| 000870 |
Catherine Kielar ; Thomas M. Wishart ; Alice Palmer ; Sybille Dihanich ; Andrew M. Wong ; Shannon L. Macauley ; Chun-Hung Chan ; Mark S. Sands ; David A. Pearce ; Jonathan D. Cooper ; Thomas H. Gillingwater [Royaume-Uni] | Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease |
| 000883 |
Juliane Neumann [Royaume-Uni, Allemagne] ; Jose Bras [États-Unis, Portugal, Royaume-Uni] ; Emma Deas [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Laura Parkkinen [Royaume-Uni] ; Robin H. Lachmann [Royaume-Uni] ; Abi Li [Royaume-Uni] ; Janice Holton [Royaume-Uni] ; Rita Guerreiro [États-Unis, Portugal, Royaume-Uni] ; Reema Paudel [Royaume-Uni] ; Badmavady Segarane [Royaume-Uni] ; Andrew Singleton [États-Unis, Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; John Hardy [Royaume-Uni] ; Henry Houlden [Royaume-Uni] ; Tamas Revesz [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] | Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease |
| 000892 |
Katerina E. Paleologou [Royaume-Uni] ; Christine L. Kragh [Danemark] ; David M. A. Mann [Royaume-Uni] ; Sultan A. Salem [Royaume-Uni] ; Rania Al-Shami [Émirats arabes unis] ; David Allsop [Royaume-Uni] ; Ahmed H. Hassan [Émirats arabes unis] ; Poul H. Jensen [Danemark] ; Omar M. A. El-Agnaf [Émirats arabes unis] | Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies |
| 000895 |
Laura Flinn [Royaume-Uni] ; Heather Mortiboys [Royaume-Uni] ; Katrin Volkmann [Allemagne] ; Reinhard W. Köster [Allemagne] ; Phillip W. Ingham [Royaume-Uni] ; Oliver Bandmann [Royaume-Uni] | Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio) |
| 000906 |
M. Selikhova [Royaume-Uni, Russie] ; D. R. Williams [Royaume-Uni, Australie] ; P. A. Kempster [Royaume-Uni, Australie] ; J. L. Holton [Royaume-Uni] ; T. Revesz [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | A clinico-pathological study of subtypes in Parkinson's disease |
| 000915 |
Nir Giladi [Israël] ; Joseph Tal [Israël] ; Tali Azulay [Israël] ; Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Eldad Melamed [Israël] ; Wolfgang Oertel [Allemagne] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne] | Validation of the freezing of gait questionnaire in patients with Parkinson's disease |
| 000920 |
Leon Poltawski [Royaume-Uni] ; Hazel Edwards [Royaume-Uni] ; Amy Todd [Royaume-Uni] ; Tim Watson [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Cherry Ann James [Royaume-Uni] | Ultrasound treatment of cutaneous side‐effects of infused apomorphine: A randomized controlled pilot study |
| 000924 |
A. Q. N. Mylne [Royaume-Uni] ; C. Griffiths [Royaume-Uni] ; C. Rooney [Royaume-Uni] ; P. Doyle [Royaume-Uni] | Trends in Parkinson’s disease related mortality in England and Wales, 1993–2006 |
| 000927 |
Cristine Alves Da Costa [France] ; Claire Sunyach [France] ; Emilie Giaime [France] ; Andrew West [États-Unis] ; Olga Corti [France] ; Alexis Brice [France] ; Stephen Safe [États-Unis] ; Patrick M. Abou-Sleiman [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] ; Hitoshi Takahashi [Japon] ; Mathew S. Goldberg [États-Unis] ; Jie Shen [États-Unis] ; Frdric Checler [France] | Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease |
| 000930 |
Laura Silveira-Moriyama [Royaume-Uni] ; Aviva Petrie [Royaume-Uni] ; David R. Williams [Australie] ; Andrew Evans [Australie] ; Regina Katzenschlager [Autriche] ; Egberto R. Barbosa [Brésil] ; Andrew Lees (neurologue) [Royaume-Uni] | The use of a color coded probability scale to interpret smell tests in suspected parkinsonism |
| 000936 |
Patrick A. Lewis [Royaume-Uni] | The function of ROCO proteins in health and disease |
| 000937 |
M. M. Wickremaratchi [Royaume-Uni] ; Y. Ben-Shlomo [Royaume-Uni] ; H. R. Morris [Royaume-Uni] | The effect of onset age on the clinical features of Parkinson’s disease |
| 000945 |
Simon P. Brooks [Royaume-Uni] ; Stephen B. Dunnett [Royaume-Uni] | Tests to assess motor phenotype in mice: a user's guide |
| 000947 |
A. C. Ludolph [Allemagne] ; J. Kassubek [Allemagne] ; B. G. Landwehrmeyer [Allemagne] ; E. Mandelkow [Allemagne] ; E. Mandelkow [Allemagne] ; D. J. Burn [Royaume-Uni] ; D. Caparros-Lefebvre [France] ; K. A. Frey [États-Unis] ; J. G. De Yebenes [Espagne] ; T. Gasser [Allemagne] ; P. Heutink [Pays-Bas] ; G. Höglinger [Allemagne] ; Z. Jamrozik [Pologne] ; K. A. Jellinger [Autriche] ; A. Kazantsev [États-Unis] ; H. Kretzschmar [Allemagne] ; A. E. Lang [Canada] ; I. Litvan [États-Unis] ; J. J. Lucas [Espagne] ; P. L. Mcgeer [Canada] ; S. Melquist [États-Unis] ; W. Oertel [Allemagne] ; M. Otto [Allemagne] ; D. Paviour [Royaume-Uni] ; T. Reum [Allemagne] ; A. Saint-Raymond [Royaume-Uni] ; J. C. Steele ; M. Tolnay [Suisse] ; H. Tumani [Allemagne] ; J. C. Van Swieten [Pays-Bas] ; M. T. Vanier [France] ; J. Vonsattel [États-Unis] ; S. Wagner [Allemagne] ; Z. K. Wszolek [États-Unis] | Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options |
| 000958 |
Matthias Elstner [Allemagne] ; Christopher M. Morris [Royaume-Uni] ; Katharina Heim [Allemagne] ; Peter Lichtner [Allemagne] ; Andreas Bender [Allemagne] ; Divya Mehta [Allemagne] ; Claudia Schulte [Allemagne] ; Manu Sharma [Allemagne] ; Gavin Hudson [Royaume-Uni] ; Stefano Goldwurm [Italie] ; Alessandro Giovanetti [Italie] ; Massimo Zeviani [Italie] ; David J. Burn [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] ; Robert H. Perry [Royaume-Uni] ; E. Jaros [Royaume-Uni] ; Rejko Krüger [Allemagne] ; H. Rich Wichmann [Allemagne] ; Stefan Schreiber [Allemagne] ; Harry Campbell [Royaume-Uni] ; James F. Wilson [Royaume-Uni] ; Alan F. Wright [Royaume-Uni] ; Malcolm Dunlop [Royaume-Uni] ; Giorgio Pistis [Italie] ; Daniela Toniolo [Italie] ; Patrick F. Chinnery [Royaume-Uni] ; Thomas Gasser [Allemagne] ; Thomas Klopstock [Allemagne] ; Thomas Meitinger [Allemagne] ; Holger Prokisch [Allemagne] ; Douglass M. Turnbull [Royaume-Uni] | Single‐cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene |
| 000963 |
Edward J. Wild [Royaume-Uni] ; Nick C. Fox [Royaume-Uni] | Serial volumetric MRI in Parkinsonian disorders |
| 000971 |
Saša R. Filipovi [Royaume-Uni] ; John C. Rothwell [Royaume-Uni] ; Bart P. Van De Warrenburg [Royaume-Uni, Pays-Bas] ; Kailash Bhatia [Royaume-Uni] | Repetitive transcranial magnetic stimulation for levodopa‐induced dyskinesias in Parkinson's disease |
| 000975 |
Iracema Leroi [Royaume-Uni] ; Ross Overshott [Royaume-Uni] ; E. Jane Byrne [Royaume-Uni] ; Emily Daniel [Royaume-Uni] ; Alistair Burns [Royaume-Uni] | Randomized controlled trial of memantine in dementia associated with Parkinson's disease |
| 000980 |
Eleanor J. Davison [Royaume-Uni] ; Kyla Pennington [Royaume-Uni] ; Chao-Chun Hung [Royaume-Uni] ; Jianhe Peng [Royaume-Uni] ; Rumana Rafiq [Royaume-Uni] ; Antje Ostareck-Lederer [Allemagne] ; Dirk H. Ostareck [Allemagne] ; Helen C. Ardley [Royaume-Uni] ; Rosamonde E. Banks [Royaume-Uni] ; Philip A. Robinson [Royaume-Uni] | Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function |
| 000981 |
David J. Brooks [Royaume-Uni] ; Klaus Seppi [Autriche] | Proposed neuroimaging criteria for the diagnosis of multiple system atrophy |
| 000993 |
William K. Gray [Royaume-Uni] ; Anthony Hildreth [Royaume-Uni] ; Julie A. Bilclough [Royaume-Uni] ; Brian H. Wood [Royaume-Uni] ; Katherine Baker [Royaume-Uni] ; Richard W. Walker [Royaume-Uni] | Physical assessment as a predictor of mortality in people with Parkinson's disease: A study over 7 years |
| 000994 |
A. H. Schapira [Royaume-Uni] ; Yves Agid [France] ; P. Barone [Italie] ; P. Jenner [Royaume-Uni] ; M. R. Lemke [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; H. Reichmann [Allemagne] ; E. Tolosa [Espagne] | Perspectives on recent advances in the understanding and treatment of Parkinson’s disease |
| 000998 |
Paul Wicks [États-Unis] ; Graeme J. A. Macphee [Royaume-Uni] | Pathological gambling amongst Parkinson's disease and ALS patients in an online community (PatientsLikeMe.com) |
| 000A01 |
Vicky L. Marshall [Royaume-Uni] ; Cornelia B. Reininger [Allemagne] ; Moritz Marquardt [Allemagne] ; Jim Patterson [Royaume-Uni] ; Donald M. Hadley [Royaume-Uni] ; Wolfgang H. Oertel [Allemagne] ; Hani T. S. Benamer [Royaume-Uni] ; Paul Kemp [Royaume-Uni] ; David Burn [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Jamie Kulisevsky [Espagne] ; Luis Cunha [Portugal] ; Durval Costa [Portugal] ; Jan Booij [Pays-Bas] ; Klaus Tatsch [Allemagne] ; K. Ray Chaudhuri [Royaume-Uni] ; Gudrun Ulm [Allemagne] ; Oliver Pogarell [Allemagne] ; Helmut Höffken [Allemagne] ; Anja Gerstner [Allemagne] ; Donald G. Grosset [Royaume-Uni] | Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3‐year European multicenter study with repeat [123I]FP‐CIT SPECT |
| 000A03 |
Christopher H. Hawkes [Royaume-Uni] ; Kelly Del Tredici [Allemagne] ; Heiko Braak [Allemagne] | Parkinson's Disease |
| 000A06 |
J. Brooks [États-Unis] ; J. Ding [États-Unis] ; J. Simon-Sanchez [États-Unis] ; C. Paisan-Ruiz [Royaume-Uni] ; A B Singleton [États-Unis] ; S W Scholz [États-Unis, Royaume-Uni] | Parkin and PINK1 mutations in early-onset Parkinson’s disease: comprehensive screening in publicly available cases and control |
| 000A16 |
Lesley Wise [Royaume-Uni] ; John Parkinson [Royaume-Uni] ; June Raine [Royaume-Uni] ; Alasdair Breckenridge [Royaume-Uni] | New approaches to drug safety: a pharmacovigilance tool kit |
| 000A17 |
Dag Aarsland [Norvège, Royaume-Uni] ; Laura Marsh [États-Unis] ; Anette Schrag [Royaume-Uni] | Neuropsychiatric symptoms in Parkinson's disease |
| 000A21 |
Naroa Ibarretxe-Bilbao [Espagne] ; Carme Junque [Espagne] ; Eduardo Tolosa [Espagne] ; Maria-Jose Marti [Espagne] ; Francesc Valldeoriola [Espagne] ; Nuria Bargallo [Espagne] ; Mojtaba Zarei [Royaume-Uni] | Neuroanatomical correlates of impaired decision‐making and facial emotion recognition in early Parkinson’s disease |
| 000A38 |
Nicola Armstrong [Royaume-Uni] ; Chris Nugent [Royaume-Uni] ; George Moore [Royaume-Uni] ; Dewar Finlay [Royaume-Uni] | Mapping User Needs to Smartphone Services for Persons with Chronic Disease |
| 000A44 |
C. E. Higham [Royaume-Uni] ; T. T. Chung [Royaume-Uni] ; J. Lawrance [Royaume-Uni] ; W. M. Drake [Royaume-Uni] ; P. J. Trainer [Royaume-Uni] | Long‐term experience of pegvisomant therapy as a treatment for acromegaly |
| 000A46 |
Sophie Molloy [Royaume-Uni] ; Thais Minett [Brésil] ; John T. O'Brien [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] ; David J. Burn [Royaume-Uni] | Levodopa use and sleep in patients with dementia with Lewy bodies |
| 000A48 |
A. H. V. Schapira [Royaume-Uni] ; M. Emre [Turquie] ; P. Jenner [Royaume-Uni] ; Werner Poewe [Autriche] | Levodopa in the treatment of Parkinson’s disease |
| 000A54 |
Coro Paisán-Ruiz [Royaume-Uni] | LRRK2 gene variation and its contribution to Parkinson disease |
| 000A56 |
Roy Elbers [Pays-Bas] ; Erwin E. H. Van Wegen [Pays-Bas] ; Lynn Rochester [Royaume-Uni] ; Victoria Hetherington [Royaume-Uni] ; Alice Nieuwboer [Belgique] ; Anne-Marie Willems [Belgique] ; Diana Jones [Royaume-Uni] ; Gert Kwakkel [Pays-Bas] | Is impact of fatigue an independent factor associated with physical activity in patients with idiopathic Parkinson's disease? |
| 000A58 |
Holger Honig [Allemagne] ; Angelo Antonini [Italie] ; Pablo Martinez-Martin [Espagne] ; Ian Forgacs [Royaume-Uni] ; Guy C. Faye [Royaume-Uni] ; Thomas Fox [Allemagne] ; Karen Fox [Allemagne] ; Francesca Mancini [Italie] ; Margherita Canesi [Italie] ; Per Odin [Allemagne] ; K. Ray Chaudhuri [Royaume-Uni] | Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life |
| 000A64 |
David J. Brooks [Royaume-Uni] | Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography |
| 000A70 |
Christine Klein [Allemagne, Canada] ; Susanne A. Schneider [Allemagne, Royaume-Uni] ; Anthony E. Lang [Canada] | Hereditary parkinsonism: Parkinson disease look‐alikes—An algorithm for clinicians to “PARK” genes and beyond |
| 000A74 |
Edward J. Newman [Royaume-Uni] ; Katherine A. Grosset [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Geographical difference in Parkinson's disease prevalence within West Scotland |
| 000A86 |
Sarah Teixeira Camargos [Brésil] ; Leonardo Oliveira Dornas [Brésil] ; Parastoo Momeni [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; John Hardy [Royaume-Uni] ; Andrew Singleton [États-Unis] ; Francisco Cardoso [Brésil] | Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: Phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations |
| 000B04 |
H. Nissinen [Finlande] ; M. Kuoppam Ki [Finlande] ; M. Leinonen [Suède] ; A. H. Schapira [Royaume-Uni] | Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis |
| 000B05 |
H. F. Harbo [Norvège] ; J. Finsterer [Autriche] ; J. Baets [Belgique] ; C. Van Broeckhoven [Belgique] ; S. Di Donato [Italie] ; B. Fontaine [France] ; P. De Jonghe [Belgique] ; A. Lossos [Israël] ; T. Lynch [Irlande (pays)] ; C. Mariotti [Italie] ; L. Schöls [Allemagne] ; A. Spinazzola [Italie] ; Z. Szolnoki [Hongrie] ; S. J. Tabrizi [Royaume-Uni] ; C. Tallaksen [Norvège] ; M. Zeviani [Italie] ; J. Burgunder [Suisse] ; T. Gasser [Allemagne] | EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington’s disease, Parkinson’s disease and dystonias |
| 000B06 |
Marian L. Evatt [États-Unis] ; K. Ray Chaudhuri [Royaume-Uni] ; Kelvin L. Chou [États-Unis] ; Ester Cubo [Espagne] ; Vanessa Hinson [États-Unis] ; Katie Kompoliti [États-Unis] ; Chengwu Yang [États-Unis] ; Werner Poewe [États-Unis] ; Olivier Rascol [Autriche] ; Cristina Sampaio [France, Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] | Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation—Critique and recommendations by movement disorders task force on rating scales for Parkinson's disease |
| 000B15 |
Nadja Van Camp [Belgique, France] ; Ines Blockx [Belgique] ; Marleen Verhoye [Belgique] ; Cindy Casteels [Belgique] ; Frea Coun [Belgique] ; Alexander Leemans [Royaume-Uni, Pays-Bas] ; Jan Sijbers [Belgique] ; Veerle Baekelandt [Belgique] ; Koen Van Laere [Belgique] ; Annemie Van Der Linden [Belgique] | Diffusion tensor imaging in a rat model of Parkinson's disease after lesioning of the nigrostriatal tract |
| 000B19 |
Susan Howell [Royaume-Uni] ; Elina Tripoliti [Royaume-Uni] ; Tim Pring [Royaume-Uni] | Delivering the Lee Silverman Voice Treatment (LSVT) by web camera: a feasibility study |
| 000B29 |
Susanne A. Schneider [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; John Hardy [Royaume-Uni] | Complicated recessive dystonia parkinsonism syndromes |
| 000B43 |
A H Evans [Australie, Royaume-Uni] ; A D Lawrence [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease |
| 000B56 |
Gráinne C. O Eeffe [Royaume-Uni] ; Andrew W. Michell [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] | Biomarkers in Huntington's and Parkinson's Disease |
| 000B72 |
Donald Grosset [Royaume-Uni] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Gianni Pezzoli [Italie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Karen Shaw [Royaume-Uni] ; Esther Cubo [Espagne] ; Pablo Martinez-Martin [Espagne] ; Olivier Rascol [France] ; Laurence Negre-Pages [France] ; Ana Senard [France] ; Johannes Schwarz [Allemagne] ; Karl Strecker [Allemagne] ; Heinz Reichmann [Allemagne] ; Alexander Storch [Allemagne] ; Matthias Löhle [Allemagne] ; Fabrizio Stocchi [Italie] ; Katherine Grosset [Royaume-Uni] | Adherence to antiparkinson medication in a multicenter European study |
| 000B75 |
Laura Silveira-Moriyama [Royaume-Uni] ; Dharshana Sirisena [Sri Lanka] ; Pasan Gamage [Sri Lanka] ; Ranjanie Gamage [Sri Lanka] ; Rohan De Silva [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Adapting the Sniffin' Sticks to diagnose Parkinson's disease in Sri Lanka |
| 000B76 |
Edward J. Newman [Royaume-Uni] ; Kieran Breen [Royaume-Uni] ; Jim Patterson [Royaume-Uni] ; Donald M. Hadley [Royaume-Uni] ; Katherine A. Grosset [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland |
| 000B87 |
Ludvic Zrinzo [Suède, Royaume-Uni] ; Laurence V. Zrinzo [Suède, Royaume-Uni] ; Stephen Tisch [Suède, Royaume-Uni] ; Patricia Dowsey Limousin [Suède, Royaume-Uni] ; Tarek A. Yousry [Suède, Royaume-Uni] ; Farhad Afshar [Suède, Royaume-Uni] ; Marwan I. Hariz [Suède, Royaume-Uni] | Stereotactic localization of the human pedunculopontine nucleus: atlas-based coordinates and validation of a magnetic resonance imaging protocol for direct localization |
| 000C02 |
Johan Antonsson [Suède] ; Ola Eriksson [Suède] ; Patric Blomstedt [Suède] ; A Tommy Bergenheim [Suède] ; Marwan I Hariz [Suède, Royaume-Uni] ; Johan Richter [Suède] ; Peter Zsigmond [Suède] ; Karin Wrdell [Suède] | Diffuse reflectance spectroscopy measurements for tissue-type discrimination during deep brain stimulation |
| 000C08 |
Nobukatsu Sawamoto [Royaume-Uni] ; Paola Piccini [Royaume-Uni] ; Gary Hotton [Royaume-Uni] ; Nicola Pavese [Royaume-Uni] ; Kris Thielemans [Royaume-Uni] ; David J. Brooks [Royaume-Uni] | Cognitive deficits and striato-frontal dopamine release in Parkinson's disease |
| 000C16 |
C. A. Davie [Royaume-Uni] | A review of Parkinson's disease |
| 000C20 |
C. Warren Olanow [États-Unis] ; Karl Kieburtz [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] | Why have we failed to achieve neuroprotection in Parkinson's disease? |
| 000C22 |
Helene Plun-Favreau [Royaume-Uni] ; Sonia Gandhi [Royaume-Uni] ; Alison Wood-Kaczmar [Royaume-Uni] ; Emma Deas [Royaume-Uni] ; Zhi Yao [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] | What Have PINK1 and HtrA2 Genes Told Us about the Role of Mitochondria in Parkinson's Disease? |
| 000C28 |
D R Williams [Royaume-Uni] ; J D Warren [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical parkinsonism |
| 000C39 |
Laura Silveira-Moriyama [Royaume-Uni] ; Margarete De Jesus Carvalho [Brésil] ; Regina Katzenschlager [Autriche] ; Aviva Petrie [Royaume-Uni] ; Ronald Ranvaud [Brésil] ; Egberto Reis Barbosa [Brésil] ; Andrew Lees (neurologue) [Royaume-Uni] | The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil |
| 000C43 |
Christopher H. Hawkes [Royaume-Uni] | The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it? |
| 000C47 |
M. E. Kalaitzakis [Royaume-Uni] ; M. B. Graeber [Royaume-Uni] ; S. M. Gentleman [Royaume-Uni] ; R. K. B. Pearce [Royaume-Uni] | The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α‐synuclein staging |
| 000C50 |
Anthony H. V. Schapira [Royaume-Uni] | The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease |
| 000C51 |
Andrew Lees (neurologue) [Royaume-Uni] ; Marianna Selikhova [Royaume-Uni] ; Luiz Augusto Andrade [Brésil] ; Charles Duyckaerts [France] | The black stuff and Konstantin Nikolaevich Tretiakoff |
| 000C59 |
Sonja Scholz [États-Unis, Royaume-Uni] ; Andrew Singleton [États-Unis] | Susceptibility genes in movement disorders |
| 000C74 |
James Scott Miners [Royaume-Uni] ; Shabnam Baig [Royaume-Uni] ; Jennifer Palmer [Royaume-Uni] ; Laura E. Palmer [Royaume-Uni] ; Patrick G. Kehoe [Royaume-Uni] ; Seth Love [Royaume-Uni] | SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer's Disease: Aβ‐Degrading Enzymes in Alzheimer's Disease |
| 000C76 |
Pablo Martinez-Martin [Espagne] ; Martine Visser [Pays-Bas] ; Carmen Rodriguez-Blazquez [Espagne] ; Johan Marinus [Pays-Bas] ; K. Ray Chaudhuri [Royaume-Uni] ; Jacobus J. Van Hilten [Pays-Bas] | SCOPA‐sleep and PDSS: Two scales for assessment of sleep disorder in Parkinson's disease |
| 000C80 |
Patrik Brundin [Suède] ; Jia-Yi Li [Suède] ; Janice L. Holton [Royaume-Uni] ; Olle Lindvall [Suède] ; Tamas Revesz [Royaume-Uni] | Research in motion: the enigma of Parkinson's disease pathology spread |
| 000C87 |
K. Ray Chaudhuri [Royaume-Uni] ; P. Martinez-Martin [Espagne] | Quantitation of non‐motor symptoms in Parkinson’s disease |
| 000C89 |
Susanne Hempel [États-Unis] ; Gill Norman [Royaume-Uni] ; Su Golder [Royaume-Uni] ; Raquel Aguiar-Ibá Ez [Royaume-Uni] ; Alison Eastwood [Royaume-Uni] | Psychosocial interventions for non‐professional carers of people with Parkinson’s disease: a systematic scoping review |
| 000C95 |
L. Ishihara-Paul [Royaume-Uni] ; N. W. J. Wainwright [Royaume-Uni] ; K. Khaw [Royaume-Uni] ; R. N. Luben [Royaume-Uni] ; A. A. Welch [Royaume-Uni] ; N. E. Day [Royaume-Uni] ; C. Brayne [Royaume-Uni] ; P. G. Surtees [Royaume-Uni] | Prospective association between emotional health and clinical evidence of Parkinson’s disease |
| 000C96 |
A. H. V. Schapira [Royaume-Uni] | Progress in neuroprotection in Parkinson’s disease |
| 000C98 |
Peter Jenner [Royaume-Uni] | Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities |
| 000D05 |
David Stuckler [Royaume-Uni] | Population Causes and Consequences of Leading Chronic Diseases: A Comparative Analysis of Prevailing Explanations |
| 000D07 |
J-P Taylor [Royaume-Uni] ; E N Rowan [Royaume-Uni] ; D. Lett [Royaume-Uni] ; J T O Rien [Royaume-Uni] ; I G Mckeith [Royaume-Uni] ; D J Burn [Royaume-Uni] | Poor attentional function predicts cognitive decline in patients with non-demented Parkinson’s disease independent of motor phenotype |
| 000D14 |
Hani T. S. Benamer [Royaume-Uni] ; Rajith De Silva [Royaume-Uni] ; Khurram A. Siddiqui ; Donald G. Grosset [Royaume-Uni] | Parkinson's disease in Arabs: A systematic review |
| 000D19 |
Peter Brown [Royaume-Uni] ; Alexandre Eusebio [Royaume-Uni] | Paradoxes of functional neurosurgery: Clues from basal ganglia recordings |
| 000D25 |
Rhona Mirsky [Royaume-Uni] ; Ashwin Woodhoo [Royaume-Uni] ; David B. Parkinson [Royaume-Uni] ; Peter Arthur-Farraj [Royaume-Uni] ; Ambily Bhaskaran [Royaume-Uni] ; Kristján R. Jessen [Royaume-Uni] | Novel signals controlling embryonic Schwann cell development, myelination and dedifferentiation |
| 000D28 |
Sean S. O'Sullivan [Royaume-Uni] ; David R. Williams [Royaume-Uni, Australie] ; David A. Gallagher [Royaume-Uni] ; Luke A. Massey [Royaume-Uni] ; Laura Silveira-Moriyama [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Nonmotor symptoms as presenting complaints in Parkinson's disease: A clinicopathological study |
| 000D38 |
Kristján R. Jessen [Royaume-Uni] ; Rhona Mirsky [Royaume-Uni] | Negative regulation of myelination: Relevance for development, injury, and demyelinating disease |
| 000D43 |
Marwan I. Hariz [Royaume-Uni, Suède] ; Stig Rehncrona [Suède] ; Niall P. Quinn [Royaume-Uni] ; Johannes D. Speelman [Pays-Bas] ; Carin Wensing [Pays-Bas] | Multicenter study on deep brain stimulation in Parkinson's disease: An independent assessment of reported adverse events at 4 years |
| 000D45 |
Peter Jenner [Royaume-Uni] | Molecular mechanisms of L-DOPA-induced dyskinesia |
| 000D57 |
Lauren I. Wallis [Royaume-Uni] ; Martyn N. J. Paley [Royaume-Uni] ; Jacqueline M. Graham [Royaume-Uni] ; Richard A. Grünewald [Royaume-Uni] ; Emma L. Wignall [Royaume-Uni] ; Harriet M. Joy [Royaume-Uni] ; Paul D. Griffiths [Royaume-Uni] | MRI assessment of basal ganglia iron deposition in Parkinson's disease |
| 000D66 |
J. Alegre-Abarrategui ; O. Ansorge [Royaume-Uni] ; M. Esiri [Royaume-Uni] ; R. Wade-Martins | LRRK2 is a component of granular alpha‐synuclein pathology in the brainstem of Parkinson's disease |
| 000D67 |
X. An [République populaire de Chine] ; R. Peng [République populaire de Chine] ; T. Li [République populaire de Chine, Royaume-Uni] ; J. Burgunder [République populaire de Chine, Singapour] ; Y. Wu [République populaire de Chine] ; W. Chen [République populaire de Chine] ; J. Zhang [République populaire de Chine] ; Y. Wang [République populaire de Chine] ; Y. Xu [République populaire de Chine] ; Y. Gou [République populaire de Chine] ; G. Yuan [République populaire de Chine] ; Z. Zhang [République populaire de Chine] | LRRK2 Gly2385Arg variant is a risk factor of Parkinson’s disease among Han‐Chinese from mainland China |
| 000D70 |
Margaret Walshe [Irlande (pays)] ; Nick Miller [Royaume-Uni] ; Margaret Leahy [Irlande (pays)] ; Aisling Murray [Irlande (pays)] | Intelligibility of dysarthric speech: perceptions of speakers and listeners |
| 000D77 |
Christopher F. Mcnicoll [États-Unis] ; Jeanne C. Latourelle [États-Unis] ; Marcy E. Macdonald [États-Unis] ; Mark F. Lew [États-Unis] ; Oksana Suchowersky [Canada] ; Christine Klein [Allemagne] ; Lawrence I. Golbe [États-Unis] ; Margery H. Mark [États-Unis] ; John H. Growdon [États-Unis] ; G. Frederick Wooten [États-Unis] ; Ray L. Watts [États-Unis] ; Mark Guttman [Canada] ; Brad A. Racette [États-Unis] ; Joel S. Perlmutter [États-Unis] ; Anwar Ahmed [États-Unis] ; Holly A. Shill [États-Unis] ; Carlos Singer [États-Unis] ; Marie H. Saint-Hilaire [États-Unis] ; Tiffany Massood [États-Unis] ; Karen W. Huskey [États-Unis] ; Anita L. Destefano [États-Unis] ; Tammy Gillis [États-Unis] ; Jayalakshmi Mysore [États-Unis] ; Stefano Goldwurm [Italie] ; Gianni Pezzoli [Italie] ; Kenneth B. Baker [États-Unis] ; Ilia Itin [États-Unis] ; Irene Litvan [États-Unis] ; Garth Nicholson [Australie] ; Alastair Corbett [Australie] ; Martha Nance [États-Unis] ; Edward Drasby [États-Unis] ; Stuart Isaacson [États-Unis] ; David J. Burn [Royaume-Uni] ; Patrick F. Chinnery [Royaume-Uni] ; Peter P. Pramstaller [Italie] ; Jomana Al-Hinti [États-Unis] ; Anette T. Moller [Danemark] ; Karen Ostergaard [Danemark] ; Scott J. Sherman [États-Unis] ; Richard Roxburgh [Nouvelle-Zélande] ; Barry Snow [Nouvelle-Zélande] ; John T. Slevin [États-Unis] ; Franca Cambi [États-Unis] ; James F. Gusella [États-Unis] ; Richard H. Myers [États-Unis] | Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD study |
| 000D84 |
R. John Dobbs [Royaume-Uni] ; Sylvia M. Dobbs [Royaume-Uni] ; Clive Weller [Royaume-Uni] ; André Charlett [Royaume-Uni] ; Ingvar T. Bjarnason ; Alan Curry [Royaume-Uni] ; David S. Ellis ; Mohammad A. A. Ibrahim ; Maria V. Mccrossan ; John O'Donohue ; Robert J. Owen [Royaume-Uni] ; Norman L. Oxlade [Royaume-Uni] ; Ashley B. Price [Royaume-Uni] ; Jeremy D. Sanderson [Royaume-Uni] ; Malur Sudhanva [Royaume-Uni] ; John Williams [Royaume-Uni] | Helicobacter Hypothesis for Idiopathic Parkinsonism: Before and Beyond |
| 000D85 |
L. Smith [Royaume-Uni] ; Andrew Greensted [Royaume-Uni] ; Jon Timmis [Royaume-Uni] | Hardware Acceleration of an Immune Network Inspired Evolutionary Algorithm for Medical Diagnosis |
| 000D90 |
Javier Simon-Sanchez [États-Unis, Espagne] ; Sonja Scholz [États-Unis, Royaume-Uni] ; Maria Del Mar Matarin [États-Unis] ; Hon-Chung Fung [Royaume-Uni, États-Unis] ; Dena Hernandez [États-Unis] ; J Raphael Gibbs [Royaume-Uni, États-Unis] ; Angela Britton [États-Unis] ; John Hardy [Royaume-Uni] ; Andrew Singleton [États-Unis] | Genomewide SNP assay reveals mutations underlying Parkinson disease |
| 000D96 |
Peter Jenner [Royaume-Uni] | Functional models of Parkinson's disease: A valuable tool in the development of novel therapies |
| 000D97 |
Aileen K. Ho [Royaume-Uni] ; John L. Bradshaw [Australie] ; Robert Iansek [Australie] | For better or worse: The effect of levodopa on speech in Parkinson's disease |
| 000E10 |
Myeong Soo Lee [Royaume-Uni, Corée du Sud] ; Byung-Cheul Shin [Corée du Sud] ; Jae Cheol Kong [Corée du Sud] ; Edzard Ernst [Royaume-Uni] | Effectiveness of acupuncture for Parkinson's disease: A systematic review |
| 000E13 |
Anthony H. V. Schapira [Royaume-Uni] ; C. Warren Olanow [États-Unis] | Drug selection and timing of initiation of treatment in early Parkinson's disease |
| 000E33 |
Angelo Antonini [Italie] ; Patrizia Berto [Italie] ; Stefania Lopatriello [Italie] ; Filippo Tamma [Italie] ; Lieven Annemans [Belgique] ; Mike Chambers [Royaume-Uni] | Cost‐effectiveness of 123I‐FP‐CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy |
| 000E35 |
M. Steiger [Royaume-Uni] | Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease |
| 000E37 |
Coro Paisán-Ruíz [États-Unis] ; Priti Nath [États-Unis] ; Nicole Washecka [États-Unis] ; J. Raphael Gibbs [États-Unis, Royaume-Uni] ; Andrew B. Singleton [États-Unis] | Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls |
| 000E45 |
J. C. Möller [Allemagne] ; K. M. Eggert [Allemagne] ; M. Unger [Allemagne] ; P. Odin [Allemagne] ; K. R. Chaudhuri [Royaume-Uni] ; W. H. Oertel [Allemagne] | Clinical risk–benefit assessment of dopamine agonists |
| 000E47 |
Daisy L. Whitehead [Royaume-Uni] ; Ann D. M. Davies [Royaume-Uni] ; Jeremy R. Playfer [Royaume-Uni] ; Christopher J. Turnbull [Royaume-Uni] | Circadian rest‐activity rhythm is altered in Parkinson's disease patients with hallucinations |
| 000E49 |
R. Caslake [Royaume-Uni] ; J N Moore [Royaume-Uni] ; J C Gordon [Royaume-Uni] ; C E Harris [Royaume-Uni] ; C. Counsell [Royaume-Uni] | Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism |
| 000E52 |
Jo Knight [Royaume-Uni] ; David Curtis [Royaume-Uni] ; Pak C. Sham [Royaume-Uni, Hong Kong] | CLUMPHAP: a simple tool for performing haplotype‐based association analysis |
| 000E57 |
L. Bet [Italie] ; S. R. Bareggi [Italie] ; F. Pacei [Italie] ; G. Bondiolotti [Italie] ; G. Meola [Italie] ; A. H. V. Schapira [Royaume-Uni] | Bimodal administration of entacapone in Parkinson’s disease patients improves motor control |
| 000E64 |
Carl E. Clarke [Royaume-Uni] | Are delayed‐start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? |
| 000E69 |
Bart P. C. Van De Warrenburg [Royaume-Uni, Pays-Bas] ; Andrew J. Church [Royaume-Uni] ; Davide Martino [Royaume-Uni, Italie] ; Paul M. Candler [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; Gavin Giovannoni [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] | Antineuronal antibodies in Parkinson's disease |
| 000E72 |
Amy K. Reeve [Royaume-Uni] ; Kim J. Krishnan [Royaume-Uni] ; Doug M. Turnbull [Royaume-Uni] | Age related mitochondrial degenerative disorders in humans |
| 000E77 |
Urs Peter Mosimann [Royaume-Uni] ; Daniel Collerton [Royaume-Uni] ; Robert Dudley [Royaume-Uni] ; Thomas Daniel Meyer [Royaume-Uni] ; Gemma Graham [Royaume-Uni] ; Jennifer Louise Dean [Royaume-Uni] ; Daniel Bearn [Royaume-Uni] ; Alison Killen [Royaume-Uni] ; Lucy Dickinson [Royaume-Uni] ; Mike Patrick Clarke [Royaume-Uni] ; Ian Grant Mckeith [Royaume-Uni] | A semi‐structured interview to assess visual hallucinations in older people |
| 000F04 |
Andrew Grupe [Royaume-Uni] ; Richard Abraham ; Yonghong Li ; Charles Rowland ; Paul Hollingworth ; Angharad Morgan ; Luke Jehu ; Ricardo Segurado ; David Stone ; Eric Schadt ; Maha Karnoub ; Petra Nowotny ; Kristina Tacey ; Joseph Catanese ; John Sninsky ; Carol Brayne ; David Rubinsztein ; Michael Gill ; Brian Lawlor ; Simon Lovestone ; Peter Holmans ; Michael O'Donovan ; John C. Morris ; Leon Thal ; Alison Goate ; Michael J. Owen ; Julie Williams [Royaume-Uni] | Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants |
| 000F12 |
Jan Zijlmans [Royaume-Uni, Pays-Bas] ; Andrew Evans [Royaume-Uni] ; Flavia Fontes [Royaume-Uni] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Svetoslav Gacinovic [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Durval Costa [Royaume-Uni, Portugal] | [123I] FP‐CIT spect study in vascular parkinsonism and Parkinson's disease |
| 000F18 |
Andrew Lees (neurologue) [Royaume-Uni] | Unresolved issues relating to the Shaking Palsy on the celebration of James Parkinson's 250th birthday |
| 000F19 |
Anne-Marie Willems [Belgique] ; Alice Nieuwboer [Belgique] ; Fabienne Chavret [Belgique] ; Kaat Desloovere [Belgique] ; René Dom [Belgique] ; Lynn Rochester [Royaume-Uni] ; Gert Kwakkel [Pays-Bas] ; Erwin Van Wegen [Pays-Bas] ; Diana Jones [Royaume-Uni] | Turning in Parkinson's disease patients and controls: The effect of auditory cues |
| 000F22 |
Morten L. Kringelbach [Royaume-Uni, Danemark] ; Ned Jenkinson [Royaume-Uni] ; Sarah L. F. Owen [Royaume-Uni] ; Tipu Z. Aziz [Royaume-Uni] | Translational principles of deep brain stimulation |
| 000F29 |
Rima Obeid [Allemagne] ; Andrew Mccaddon [Royaume-Uni] ; Wolfgang Herrmann [Allemagne] | The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases |
| 000F35 |
Nadia Rosenthal [Italie] ; Steve Brown [Royaume-Uni] | The mouse ascending: perspectives for human-disease models |
| 000F36 |
Hlne Plun-Favreau [Royaume-Uni] ; Kristina Klupsch [Royaume-Uni] ; Nicoleta Moisoi [Royaume-Uni] ; Sonia Gandhi [Royaume-Uni] ; Svend Kjaer [Royaume-Uni] ; David Frith [Royaume-Uni] ; Kirsten Harvey [Royaume-Uni] ; Emma Deas [Royaume-Uni] ; Robert J. Harvey [Royaume-Uni] ; Neil Mcdonald [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] ; L. Miguel Martins [Royaume-Uni] ; Julian Downward [Royaume-Uni] | The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1 |
| 000F44 |
An Goris [Royaume-Uni, Belgique] ; Caroline H. Williams-Gray [Royaume-Uni] ; Graeme R. Clark [Royaume-Uni] ; Thomas Foltynie [Royaume-Uni] ; Simon J. G. Lewis [Royaume-Uni] ; Joanne Brown [Royaume-Uni] ; Maria Ban [Royaume-Uni] ; Maria G. Spillantini [Royaume-Uni] ; Alastair Compston [Royaume-Uni] ; David J. Burn [Royaume-Uni] ; Patrick F. Chinnery [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] ; Stephen J. Sawcer [Royaume-Uni] | Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease |
| 000F49 |
Frauke Boddy [Royaume-Uni] ; Elise N. Rowan [Royaume-Uni] ; Debbie Lett [Royaume-Uni] ; John T. O'Brien [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] ; David J. Burn [Royaume-Uni] | Subjectively reported sleep quality and excessive daytime somnolence in Parkinson's disease with and without dementia, dementia with Lewy bodies and Alzheimer's disease |
| 000F50 |
M. J. Hurley [Royaume-Uni] ; P. H. Patel [Royaume-Uni] ; M. J. Jackson [Royaume-Uni] ; L. A. Smith [Royaume-Uni] ; S. Rose [Royaume-Uni] ; P. Jenner [Royaume-Uni] | Striatal leucine‐rich repeat kinase 2 mRNA is increased in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned common marmosets (Callithrix jacchus) with l‐3, 4‐dihydroxyphenylalanine methyl ester‐induced dyskinesia |
| 000F57 |
Margaret A. Piggott [Royaume-Uni] ; Clive G. Ballard [Royaume-Uni] ; Elise Rowan [Royaume-Uni] ; Clive Holmes [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] ; Evelyn Jaros [Royaume-Uni] ; Robert H. Perry [Royaume-Uni] ; Elaine K. Perry [Royaume-Uni] | Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline |
| 000F59 |
Lianna Ishihara [Royaume-Uni] ; Rachel A. Gibson [Royaume-Uni] ; Liling Warren [États-Unis] ; Rim Amouri [Tunisie] ; Kelly Lyons [États-Unis] ; Catherine Wielinski [États-Unis] ; Christine Hunter [États-Unis] ; Jina E. Swartz [Royaume-Uni] ; Ramu Elango [Royaume-Uni] ; P. Anthony Akkari [États-Unis] ; David Leppert [Royaume-Uni] ; Linda Surh [Royaume-Uni] ; Kevin H. Reeves [États-Unis] ; Siwan Thomas [Royaume-Uni] ; Leigh Ragone [États-Unis] ; Nobutaka Hattori [Japon] ; Rajesh Pahwa [États-Unis] ; Joseph Jankovic [États-Unis] ; Martha Nance [États-Unis] ; Alan Freeman [États-Unis] ; Neziha Gouider-Khouja [Tunisie] ; Mounir Kefi [Tunisie] ; Mourad Zouari [Tunisie] ; Samia Ben Sassi [Tunisie] ; Samia Ben Yahmed [Tunisie] ; Ghada El Euch-Fayeche [Tunisie] ; Lefkos Middleton [Royaume-Uni] ; David J. Burn [Royaume-Uni] ; Ray L. Watts [États-Unis] ; Faycal Hentati [Tunisie] | Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families |
| 000F60 |
Nir Giladi [Israël] ; Babak Boroojerdi [Allemagne] ; Amos D. Korczyn [Israël] ; David J. Burn [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni] | Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole |
| 000F61 |
Christoph Scherfler [Autriche] ; Johannes Schwarz [Allemagne] ; Angelo Antonini [Italie] ; Donald Grosset [Royaume-Uni] ; Francesc Valldeoriola [Espagne] ; Kenneth Marek [États-Unis] ; Wolfgang Oertel [Allemagne] ; Eduardo Tolosa [Espagne] ; Andrew Lees (neurologue) [Royaume-Uni] ; Werner Poewe [Autriche] | Role of DAT‐SPECT in the diagnostic work up of Parkinsonism |
| 000F68 |
G. Waldemar [Danemark] ; B. Dubois [France] ; M. Emre [Turquie] ; J. Georges [Luxembourg (pays)] ; I. G. Mckeith [Royaume-Uni] ; M. Rossor [Royaume-Uni] ; P. Scheltens [Pays-Bas] ; P. Tariska [Hongrie] ; B. Winblad [Suède] | Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline |
| 000F69 |
Anette Schrag [Royaume-Uni] ; Richard Dodel [Allemagne] ; Annika Spottke [Allemagne] ; Bernhard Bornschein [Autriche] ; Uwe Siebert [Autriche, États-Unis] ; Niall P. Quinn [Royaume-Uni] | Rate of clinical progression in Parkinson's disease. A prospective study |
| 000F72 |
Timothy M. Fountaine [Royaume-Uni] ; Richard Wade-Martins [Royaume-Uni] | RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport |
| 000F84 |
Andrew J. Lawrence [Royaume-Uni] ; Andrew D. Blackwell [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] ; Francesca Spagnolo [Italie] ; Luke Clark [Royaume-Uni] ; Michael R. F. Aitken [Royaume-Uni] ; Barbara J. Sahakian [Royaume-Uni] | Predictors of punding in Parkinson's disease: Results from a questionnaire survey |
| 000F90 |
David A. Gallagher [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Andrew H. Evans [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Anette Schrag [Royaume-Uni] | Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series |
| 001028 |
Bhomraj Thanvi [Royaume-Uni] ; Nelson Lo ; Tom Robinson | Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment |
| 001050 |
Anthony H. V. Schapira [Royaume-Uni] | Future directions in the treatment of Parkinson's disease |
| 001057 |
Lianna S. Ishihara [Royaume-Uni] ; Anne Cheesbrough [Royaume-Uni] ; Carol Brayne [Royaume-Uni] ; Anette Schrag [Royaume-Uni] | Estimated life expectancy of Parkinson’s patients compared with the UK population |
| 001072 |
Dominic C. Paviour [Royaume-Uni] ; John S. Thornton [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; H. Rolf J Ger [Royaume-Uni] | Diffusion‐weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple‐system atrophy from progressive supranuclear palsy |
| 001075 |
Bruno Dubois [France] ; David Burn [Royaume-Uni] ; Christopher Goetz [États-Unis] ; Dag Aarsland [Norvège] ; Richard G. Brown [Royaume-Uni] ; Gerald A. Broe [Australie] ; Dennis Dickson [États-Unis] ; Charles Duyckaerts [France] ; Jefferey Cummings [États-Unis] ; Serge Gauthier [Canada] ; Amos Korczyn [Israël] ; Andrew Lees (neurologue) [Royaume-Uni] ; Richard Levy [France] ; Irene Litvan [États-Unis] ; Yoshikuni Mizuno [Japon] ; Ian G. Mckeith [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Eduardo Tolosa [Espagne] ; Murat Emre [Turquie] | Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force |
| 001076 |
Bernard Ravina [États-Unis] ; Karen Marder [États-Unis] ; Hubert H. Fernandez [États-Unis] ; Joseph H. Friedman [États-Unis] ; William Mcdonald [États-Unis] ; Diane Murphy [États-Unis] ; Dag Aarsland [États-Unis] ; Debra Babcock [États-Unis] ; Jefferey Cummings [États-Unis] ; Jean Endicott [États-Unis] ; Stewart Factor [États-Unis] ; Wendy Galpern [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; Laura Marsh [États-Unis] ; Mark Stacy [États-Unis] ; Katrina Gwinn-Hardy [États-Unis] ; Valerie Voon [États-Unis] ; Christopher Goetz [États-Unis] | Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group |
| 001098 |
Murat Emre [Turquie] ; Dag Aarsland [Norvège] ; Richard Brown [Royaume-Uni] ; David J. Burn [Royaume-Uni] ; Charles Duyckaerts [France] ; Yoshikino Mizuno [Japon] ; Gerald Anthony Broe [Australie] ; Jeffrey Cummings [États-Unis] ; Dennis W. Dickson [États-Unis] ; Serge Gauthier [Canada] ; Jennifer Goldman [États-Unis] ; Christopher Goetz [États-Unis] ; Amos Korczyn [Israël] ; Andrew Lees (neurologue) [Royaume-Uni] ; Richard Levy [France] ; Irene Litvan [États-Unis] ; Ian Mckeith [Royaume-Uni] ; Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; Christina Sampaio [Portugal] ; Eduardo Tolosa [Espagne] ; Bruno Dubois [France] | Clinical diagnostic criteria for dementia associated with Parkinson's disease |
| 001101 |
Paul T. Francis [Royaume-Uni] ; Elaine K. Perry [Royaume-Uni] | Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies |
| 001105 |
Adolfo Mínguez-Castellanos [Espagne] ; Francisco Escamilla-Sevilla [Espagne] ; Gary R. Hotton [Royaume-Uni] ; Juan J. Toledo-Aral [Espagne] ; Ángel Ortega-Moreno [Espagne] ; Sim N Méndez-Ferrer [Espagne] ; José M. Martín-Linares [Espagne] ; Majed J. Katati [Espagne] ; Pablo Mir [Espagne] ; Javier Villadiego [Espagne] ; Miguel Meersmans [Espagne] ; Miguel Pérez-García [Espagne] ; David J. Brooks [Royaume-Uni] ; Ventura Arjona [Espagne] ; José L Pez-Barneo [Espagne] | Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study |
| 001136 |
D. Grosset [Royaume-Uni] ; L. Taurah [Royaume-Uni] ; D J Burn [Royaume-Uni] ; D. Macmahon [Royaume-Uni] ; A. Forbes [Royaume-Uni] ; K. Turner [Royaume-Uni] ; A. Bowron [Royaume-Uni] ; R. Walker [Royaume-Uni] ; L. Findley [Royaume-Uni] ; O. Foster [Royaume-Uni] ; K. Patel [Royaume-Uni] ; C. Clough [Royaume-Uni] ; B. Castleton [Royaume-Uni] ; S. Smith [Royaume-Uni] ; G. Carey [Royaume-Uni] ; T. Murphy [Royaume-Uni] ; J. Hill [Royaume-Uni] ; U. Brechany [Royaume-Uni] ; P. Mcgee [Royaume-Uni] ; S. Reading [Royaume-Uni] ; G. Brand [Royaume-Uni] ; L. Kelly [Royaume-Uni] ; K. Breen [Royaume-Uni] ; S. Ford [Royaume-Uni] ; M. Baker [Royaume-Uni] ; A. Williams [Royaume-Uni] ; J. Hearne [Royaume-Uni] ; N. Qizilbash [Royaume-Uni] ; K Ray Chaudhuri [Royaume-Uni] | A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis |
| 001137 |
Ruth M. Pickering [Royaume-Uni] ; Yvette A. M. Grimbergen [Pays-Bas] ; Una Rigney [Royaume-Uni] ; Ann Ashburn [Royaume-Uni] ; Gordon Mazibrada [Royaume-Uni] ; Brian Wood [Royaume-Uni] ; Peggy Gray [Canada] ; Graham Kerr [Australie] ; Bastiaan R. Bloem [Pays-Bas] | A meta‐analysis of six prospective studies of falling in Parkinson's disease |
| 001140 |
Carlos Singer [États-Unis] ; Janice Lamb [Royaume-Uni] ; Amanda Ellis [Royaume-Uni] ; Gary Layton [Royaume-Uni] | A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease |
| 001144 |
Puneet Plaha [Royaume-Uni] ; Y. Ben-Shlomo [Royaume-Uni] ; Nikunj K. Patel [Royaume-Uni] ; Steven S. Gill [Royaume-Uni] | Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism |
| 001147 |
Finlay D. Dick [Royaume-Uni] | Parkinson's disease and pesticide exposures |
| 001148 |
S. Gandhi ; M. M. K. Muqit ; L. Stanyer ; D. G. Healy ; P. M. Abou-Sleiman ; I. Hargreaves ; S. Heales ; M. Ganguly ; L. Parsons ; Andrew Lees (neurologue) [Royaume-Uni] ; D. S. Latchman [Royaume-Uni] ; J. L. Holton ; N. W. Wood ; T. Revesz | PINK1 protein in normal human brain and Parkinson's disease |
| 001151 |
Tara M. Caffrey ; Catharine Joachim [Royaume-Uni] ; Silvia Paracchini ; Margaret M. Esiri [Royaume-Uni] ; Richard Wade-Martins [Royaume-Uni] | Haplotype-specific expression of exon 10 at the human MAPT locus |
| 001153 |
Justin Sauer [Royaume-Uni] ; Dominic H. Ffytche [Royaume-Uni] ; Clive Ballard [Royaume-Uni] ; Richard G. Brown [Royaume-Uni] ; Robert Howard [Royaume-Uni] | Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity |
| 001161 |
Lianna Ishihara [Royaume-Uni] ; Carol Brayne [Royaume-Uni] | What is the evidence for a premorbid parkinsonian personality: A systematic review |
| 001177 |
Anthony H. V. Schapira [Royaume-Uni, Espagne] ; Jose Obeso [Royaume-Uni, Espagne] | Timing of treatment initiation in Parkinson's disease: A need for reappraisal? |
| 001180 |
M. Sharma [Allemagne] ; J C Mueller [Allemagne] ; A. Zimprich [Autriche] ; P. Lichtner [Allemagne] ; A. Hofer [Allemagne] ; P. Leitner [Allemagne] ; S. Maass [Allemagne] ; D. Berg [Allemagne] ; A. Dürr [France] ; V. Bonifati [Italie] ; G. De Michele [Pays-Bas] ; B. Oostra [Italie] ; A. Brice [France] ; N W Wood [Royaume-Uni] ; B. Muller-Myhsok [Allemagne] ; T. Gasser [Allemagne] | The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson’s disease in European populations |
| 001181 |
David C. Rubinsztein [Royaume-Uni] | The roles of intracellular protein-degradation pathways in neurodegeneration |
| 001183 |
C M Wright [Royaume-Uni] ; K N Parkinson [Royaume-Uni] ; R F Drewett [Royaume-Uni] | The influence of maternal socioeconomic and emotional factors on infant weight gain and weight faltering (failure to thrive): data from a prospective birth cohort |
| 001185 |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease |
| 001186 |
Christian Johannes Gloeckner ; Norbert Kinkl ; Annette Schumacher ; Ralf J. Braun ; Eric O'Neill [Royaume-Uni] ; Thomas Meitinger ; Walter Kolch [Royaume-Uni] ; Holger Prokisch ; Marius Ueffing [Allemagne] | The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity |
| 001187 |
Patricia L. Whetzel ; Helen Parkinson [Royaume-Uni] ; Helen C. Causton [Royaume-Uni] ; Liju Fan [États-Unis] ; Jennifer Fostel [États-Unis] ; Gilberto Fragoso [États-Unis] ; Laurence Game [Royaume-Uni] ; Mervi Heiskanen [États-Unis] ; Norman Morrison [Royaume-Uni] ; Philippe Rocca-Serra [Royaume-Uni] ; Susanna-Assunta Sansone [Royaume-Uni] ; Chris Taylor [Royaume-Uni] ; Joseph White [États-Unis] ; Christian J. Stoeckert | The MGED Ontology: a resource for semantics-based description of microarray experiments |
| 001205 |
Alexander L. Green [Royaume-Uni] ; Richard G. Bittar [Royaume-Uni] ; Peter Bain [Royaume-Uni] ; Richard B. Scott [Royaume-Uni] ; Carol Joint [Royaume-Uni] ; Ralph Gregory [Royaume-Uni] ; Tipu Z. Aziz [Royaume-Uni] | STN vs. Pallidal Stimulation in Parkinson Disease: Improvement With Experience and Better Patient Selection |
| 001206 |
M. Horstink [Pays-Bas] ; E. Tolosa [Espagne] ; U. Bonuccelli [Italie] ; G. Deuschl [Allemagne] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; J. P. Larsen [Norvège] ; A. Lees [Royaume-Uni] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; C. Sampaio [Portugal] | Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease |
| 001207 |
M. Horstink [Pays-Bas] ; E. Tolosa [Espagne] ; U. Bonuccelli [Italie] ; G. Deuschl [Allemagne] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; J. P. Larsen [Norvège] ; A. Lees [Royaume-Uni] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; C. Sampaio [Portugal] | Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease |
| 001208 |
Dominic C. Paviour [Royaume-Uni] ; Shona L. Price [Royaume-Uni] ; Marjan Jahanshahi [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Nick C. Fox [Royaume-Uni] | Regional brain volumes distinguish PSP, MSA‐P, and PD: MRI‐based clinico‐radiological correlations |
| 001214 |
Anthony E. Lang [Canada] ; Steven Gill [Royaume-Uni] ; Nik K. Patel [Royaume-Uni] ; Andres Lozano [Canada] ; John G. Nutt [États-Unis] ; Richard Penn [États-Unis] ; David J. Brooks [Royaume-Uni] ; Gary Hotton [Royaume-Uni] ; Elena Moro [Canada] ; Peter Heywood [Canada] ; Matthew A. Brodsky [États-Unis] ; Kim Burchiel [États-Unis] ; Patrick Kelly [États-Unis] ; Arif Dalvi [États-Unis] ; Burton Scott [États-Unis] ; Mark Stacy [États-Unis] ; Dennis Turner [États-Unis] ; V. G. Frederich Wooten [États-Unis] ; William J. Elias [États-Unis] ; Edward R. Laws [États-Unis] ; Vijay Dhawan [États-Unis] ; A. Jon Stoessl [Canada] ; James Matcham [Royaume-Uni] ; Robert J. Coffey [États-Unis] ; Michael Traub [États-Unis] | Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease |
| 001220 |
Stephen B. Dunnett [Royaume-Uni] ; Anders Bjrklund [Suède] | Prospects for new restorative and neuroprotective treatments in Parkinson's disease |
| 001230 |
Kate S. M. Taylor [Royaume-Uni] ; Carl E. Counsell [Royaume-Uni] ; Clare E. Harris [Royaume-Uni] ; Joanna C. Gordon [Royaume-Uni] ; W. Cairns S. Smith [Royaume-Uni] | Pilot study of the incidence and prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: Methods and preliminary results |
| 001235 |
Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lled [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne] | Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study |
| 001246 |
Liesl M. Allcock [Royaume-Uni] ; Rose Anne Kenny [Royaume-Uni] ; Urs Peter Mosimann [Royaume-Uni] ; Sherley Tordoff [Royaume-Uni] ; Keith A. Wesnes [Royaume-Uni] ; Anthony J. Hildreth [Royaume-Uni] ; David J. Burn [Royaume-Uni] | Orthostatic hypotension in Parkinson's disease: association with cognitive decline? |
| 001250 |
Anthony H. V. Schapira [Royaume-Uni] ; Erwan Bezard [France] ; Jonathan Brotchie [Canada] ; Frdric Calon [Canada] ; Graham L. Collingridge [Royaume-Uni] ; Borris Ferger [Allemagne] ; Bastian Hengerer [Allemagne] ; Etienne Hirsch [France] ; Peter Jenner [Royaume-Uni] ; Nicolas Le Novre [Royaume-Uni] ; Jos A. Obeso [Espagne] ; Michael A. Schwarzschild [États-Unis] ; Umberto Spampinato [France] ; Giora Davidai [États-Unis] | Novel pharmacological targets for the treatment of Parkinson's disease |
| 001252 |
Paola Piccini [Royaume-Uni] ; David J. Brooks [Royaume-Uni] | New developments of brain imaging for Parkinson's disease and related disorders |
| 001260 |
Anette Schrag [Royaume-Uni] ; Cristina Sampaio [Portugal] ; Nicholas Counsell [Royaume-Uni] ; Werner Poewe [Autriche] | Minimal clinically important change on the unified Parkinson's disease rating scale |
| 001262 |
K A Grosset ; I. Bone ; J L Reid [Royaume-Uni] ; D. Grosset | Measuring therapy adherence in Parkinson’s disease: a comparison of methods |
| 001268 |
Saskia Biskup [États-Unis] ; Darren J. Moore [États-Unis] ; Fulvio Celsi [Norvège] ; Shinji Higashi [Japon, Royaume-Uni] ; Andrew B. West [États-Unis] ; Shaida A. Andrabi [États-Unis] ; Kaisa Kurkinen [États-Unis] ; Seong-Woon Yu [États-Unis] ; Joseph M. Savitt [États-Unis] ; Henry J. Waldvogel [Nouvelle-Zélande] ; Richard L. M. Faull [Nouvelle-Zélande] ; Piers C. Emson [Royaume-Uni] ; Reidun Torp [Norvège] ; Ole P. Ottersen [Norvège] ; Ted M. Dawson [États-Unis] ; Valina L. Dawson [États-Unis] | Localization of LRRK2 to membranous and vesicular structures in mammalian brain |
| 001270 |
Nick Miller [Royaume-Uni] ; Emma Noble [Royaume-Uni] ; Diana Jones ; David Burn | Life with communication changes in Parkinson’s disease |
| 001293 |
Charles E. Glatt [États-Unis] ; Angelika D. Wahner ; Daniel J. White [Royaume-Uni] ; Andres Ruiz-Linares [Royaume-Uni] ; Beate Ritz | Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women |
| 001302 |
Patrick M. Abou-Sleiman [Royaume-Uni] ; Miratul M. K. Muqit [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] | Expanding insights of mitochondrial dysfunction in Parkinson's disease |
| 001313 |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Roshan Cools [Royaume-Uni] ; Paul Krack [France] ; Valérie Fraix [France] ; Alina Batir [France] ; Stephan Chabardès [France] ; Alim-Louis Benabid [France] ; Trevor W. Robbins [Royaume-Uni] ; Pierre Pollak [France] | Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease |
| 001316 |
Eman M. Khedr [Égypte] ; John C. Rothwell [Royaume-Uni] ; Ola A. Shawky [Égypte] ; Mohamed A. Ahmed [Égypte] ; Ahmed Hamdy [Égypte] | Effect of daily repetitive transcranial magnetic stimulation on motor performance in Parkinson's disease |
| 001317 |
Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees (neurologue) [Royaume-Uni] | Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study |
| 001322 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa |
| 001330 |
Ali R. Rezai [États-Unis] ; Brian H. Kopell [États-Unis] ; Robert E. Gross [États-Unis] ; Jerrold L. Vitek [États-Unis] ; Ashwini D. Sharan [États-Unis] ; Patricia Limousin [Royaume-Uni] ; Alim-Louis Benabid [France] | Deep brain stimulation for Parkinson's disease: Surgical issues |
| 001332 |
Andrew H. Evans [Royaume-Uni] ; Nicola Pavese [Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Yen F. Tai [Royaume-Uni] ; Silke Appel [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; David J. Brooks [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Paola Piccini [Royaume-Uni] | Compulsive drug use linked to sensitized ventral striatal dopamine transmission |
| 001337 |
Liesl M. Allcock [Royaume-Uni] ; Rose Anne Kenny [Royaume-Uni] ; David J. Burn [Royaume-Uni] | Clinical phenotype of subjects with Parkinson's disease and orthostatic hypotension: Autonomic symptom and demographic comparison |
| 001362 |
Rebecca E. Colebrooke [Royaume-Uni] ; Trevor Humby [Royaume-Uni] ; Patrick J. Lynch [Royaume-Uni] ; Daniel P. Mcgowan [Royaume-Uni] ; Jing Xia [Royaume-Uni] ; Piers C. Emson [Royaume-Uni] | Age‐related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease |
| 001366 |
L. Ishihara [Royaume-Uni] ; C. Brayne [Royaume-Uni] | A systematic review of depression and mental illness preceding Parkinson's disease |
| 001370 |
Nicolas Pineda-Trujillo [Royaume-Uni, Colombie] ; Maria Apergi [Royaume-Uni] ; Sonia Moreno [Colombie] ; William Arias [Colombie] ; Suzanne Lesage [France] ; Alejandro Franco [Colombie] ; Diego Sepulveda-Falla [Colombie] ; David Cano [Colombie] ; Omar Buriticá [Colombie] ; David Pineda [Colombie] ; Carlos Santiago Uribe [Colombie] ; Justo Garcia De Yebenes [Espagne] ; Andrew Lees (neurologue) [Royaume-Uni] ; Alexis Brice [France] ; Gabriel Bedoya [Colombie] ; Francisco Lopera [Colombie] ; Andres Ruiz-Linares [Royaume-Uni, Colombie] | A genetic cluster of early onset Parkinson's disease in a Colombian population |
| 001374 |
Frank Böckler [Royaume-Uni, Allemagne] | Rezeptor‐vermittelte Parkinson‐Therapeutika. Konkurrenz für den “Goldstandard” L‐DOPA? |
| 001392 |
Mahmoud M. Iravani [Royaume-Uni] ; Sergio Costa [Royaume-Uni] ; Ghassan Al-Bargouthy [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Mikko Kuoppam Ki [Royaume-Uni] ; Jose A. Obeso [Espagne] ; Peter Jenner [Royaume-Uni] | Unilateral pallidotomy in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets exhibiting levodopa‐induced dyskinesia |
| 001396 |
Katherine Grosset [Royaume-Uni] ; Donald Grosset [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Trial of subtherapeutic pergolide in de novo Parkinson's disease |
| 001405 |
Manoj Mishra [Royaume-Uni] ; Paul Durrington [Royaume-Uni] ; Mike Mackness [Royaume-Uni] ; Kirk W. Siddals ; Kalpana Kaushal ; Rob Davies [Royaume-Uni] ; Martin Gibson ; David W. Ray [Royaume-Uni] | The effect of atorvastatin on serum lipoproteins in acromegaly |
| 001406 |
Mahmoud M. Iravani [Royaume-Uni] ; Clement C. M. Leung [Royaume-Uni] ; Mona Sadeghian [Royaume-Uni] ; Claire O. Haddon [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | The acute and the long‐term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation |
| 001410 |
Michel Goedert [Royaume-Uni] | Tau gene mutations and their effects |
| 001411 |
N A Hamid [Royaume-Uni] ; R D Mitchell [Royaume-Uni] ; P. Mocroft [Royaume-Uni] ; G W M. Westby [Royaume-Uni] ; J. Milner [Royaume-Uni] ; H. Pall [Royaume-Uni] | Targeting the subthalamic nucleus for deep brain stimulation: technical approach and fusion of pre- and postoperative MR images to define accuracy of lead placement |
| 001415 |
Katherine A. Grosset [Royaume-Uni] ; Ian Bone [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Suboptimal medication adherence in Parkinson's disease |
| 001417 |
Colum D. Mackinnon [États-Unis] ; Ruth M. Webb [Royaume-Uni] ; Paul Silberstein [Royaume-Uni] ; Steven Tisch [Royaume-Uni] ; Peter Asselman [Royaume-Uni] ; Patricia Limousin [Royaume-Uni] ; John C. Rothwell [Royaume-Uni] | Stimulation through electrodes implanted near the subthalamic nucleus activates projections to motor areas of cerebral cortex in patients with Parkinson's disease |
| 001435 |
Anthony Schapira [Royaume-Uni] ; Guy Bate [Royaume-Uni] ; Peter Kirkpatrick | Rasagiline |
| 001441 |
Louise M. Allan [Royaume-Uni] ; Clive G. Ballard [Royaume-Uni] ; David J. Burn [Royaume-Uni] ; Rose Anne Kenny [Royaume-Uni] | Prevalence and Severity of Gait Disorders in Alzheimer's and Non‐Alzheimer's Dementias |
| 001444 |
M. Kliegel [Suisse] ; L H Phillips [Royaume-Uni] ; U. Lemke [Suisse] ; Ute A. Kopp [Allemagne] | Planning and realisation of complex intentions in patients with Parkinson’s disease |
| 001445 |
Ross Corkrey [Royaume-Uni] ; Lynne Parkinson [Australie] ; Lucy Bates [Australie] ; Sue Green [Australie] ; Aye Thidar Htun [Australie] | Pilot of a novel cervical screening intervention: interactive voice response |
| 001447 |
David A. Stone [Royaume-Uni, États-Unis] ; Catherine E. Kerr [États-Unis] ; Eric Jacobson [États-Unis] ; Lisa A. Conboy Scd [États-Unis] ; Ted J. Kaptchuk [États-Unis] | Patient expectations in placebo‐controlled randomized clinical trials |
| 001448 |
A. C. Williams ; L. S. Cartwright [Royaume-Uni] ; D. B. Ramsden [Royaume-Uni] | Parkinson's disease: the first common neurological disease due to auto-intoxication? |
| 001460 |
S M Hague [Royaume-Uni] ; S. Klaffke [Royaume-Uni] ; O. Bandmann [Royaume-Uni] | Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease |
| 001461 |
Naheed L. Khan ; Shushant Jain ; John M. Lynch ; Nicola Pavese ; Patrick Abou-Sleiman ; Janice L. Holton ; Daniel G. Healy ; William P. Gilks ; Mary G. Sweeney ; Milan Ganguly ; Vaneesha Gibbons ; Sonia Gandhi ; Jenny Vaughan ; Louise H. Eunson ; Regina Katzenschlager ; Juliet Gayton ; Graham Lennox ; Tamas Revesz ; David Nicholl [Royaume-Uni] ; Kailash P. Bhatia ; Niall Quinn ; David Brooks ; Andrew Lees (neurologue) [Royaume-Uni] ; Mary B. Davis ; Paola Piccini ; Andrew B. Singleton [États-Unis] ; Nicholas W. Wood | Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data |
| 001462 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Mikko Kuoppamaki [Royaume-Uni, États-Unis] ; Warren Olanow [Finlande] ; Peter Jenner [Royaume-Uni] | Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates |
| 001465 |
Sonia Gandhi [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] | Molecular pathogenesis of Parkinson's disease |
| 001468 |
Katherine A. Grosset [Royaume-Uni] ; John L. Reid [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Medicine‐taking behavior: Implications of suboptimal compliance in Parkinson's disease |
| 001470 |
Peter P. Pramstaller [Italie, Allemagne] ; Michael G. Schlossmacher [États-Unis] ; Thomas S. Jacques [Royaume-Uni] ; Francesco Scaravilli [Royaume-Uni] ; Cordula Eskelson [Allemagne] ; Imelda Pepivani [États-Unis] ; Katja Hedrich [Allemagne] ; Susanna Adel [Allemagne] ; Melissa Gonzales-Mcneal [États-Unis] ; Rüdiger Hilker [Allemagne] ; Patricia L. Kramer [États-Unis] ; Christine Klein [Allemagne] | Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers |
| 001471 |
Catharine A. Winstanley [Royaume-Uni] ; Christelle Baunez [France] ; David E. H. Theobald [Royaume-Uni] ; Trevor W. Robbins [Royaume-Uni] | Lesions to the subthalamic nucleus decrease impulsive choice but impair autoshaping in rats: the importance of the basal ganglia in Pavlovian conditioning and impulse control |
| 001472 |
Eilís Dowd [Royaume-Uni] ; Christelle Monville [Royaume-Uni] ; Eduardo M. Torres [Royaume-Uni] ; Liang-Fong Wong [Royaume-Uni] ; Mimoun Azzouz [Royaume-Uni] ; Nicholas D. Mazarakis [Royaume-Uni] ; Stephen B. Dunnett [Royaume-Uni] | Lentivector‐mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model |
| 001474 |
Javed Ehtisham [Royaume-Uni] ; Hugh Watkins [Royaume-Uni] | Is Wolff‐Parkinson‐White Syndrome a Genetic Disease? |
| 001478 |
Joanna Iczkiewicz [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat |
| 001481 |
Mark Stacy [États-Unis] ; Annette Bowron [Royaume-Uni] ; Mark Guttman [Canada] ; Robert Hauser [États-Unis] ; Kim Hughes [Royaume-Uni] ; Jan Petter Larsen [Norvège] ; Peter Lewitt [États-Unis] ; Wolfgang Oertel [Allemagne] ; Niall Quinn [Royaume-Uni] ; Kapil Sethi [États-Unis] ; Fabrizio Stocchi [Italie] | Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment |
| 001483 |
Felix Geser [Autriche] ; Gregor K. Wenning [Autriche] ; Werner Poewe [Autriche] ; Ian Mckeith [Royaume-Uni] | How to diagnose dementia with Lewy bodies: State of the art |
| 001494 |
C. A. Davie ; A. H. V. Schapira [Royaume-Uni] | First-line Treatment in Parkinson’s Disease |
| 001499 |
M. Péchevis [France] ; C. E. Clarke [Royaume-Uni] ; P. Vieregge [Allemagne] ; B. Khoshnood [France] ; C. Deschaseaux-Voinet [France] ; G. Berdeaux [France] ; M. Ziegler [France] | Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study |
| 001509 |
Philippe Remy [France] ; Miroslava Doder [France] ; Andrew Lees (neurologue) [Royaume-Uni, France] ; Nora Turjanski [France] ; David Brooks [France] | Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system |
| 001513 |
Jordi Clarimon [États-Unis] ; Janel Johnson [États-Unis] ; Okan Dogu [Turquie] ; Wagner Horta [Brésil] ; Naheed Khan [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; John Hardy [États-Unis] ; Andrew Singleton [États-Unis] | Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease |
| 001516 |
Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Hughes [Australie] ; Andrew Evans [Royaume-Uni] ; Alice J. Manson [Royaume-Uni] ; Marion Hoffman [Australie] ; Lesley Swinn [Royaume-Uni] ; Hilary Watt [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges |
| 001525 |
N. M. Warren [Royaume-Uni] ; M. A. Piggott [Royaume-Uni] ; E. K. Perry [Royaume-Uni] ; D. J. Burn [Royaume-Uni] | Cholinergic systems in progressive supranuclear palsy |
| 001526 |
Serge Pinto [France, Royaume-Uni] ; Michèle Gentil [France] ; Paul Krack [France] ; Paul Sauleau [France] ; Valérie Fraix [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] | Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech |
| 001540 |
Dag Aarsland [Norvège] ; Julia Zaccai [Royaume-Uni] ; Carol Brayne [Royaume-Uni] | A systematic review of prevalence studies of dementia in Parkinson's disease |
| 001545 |
Mahmoud M. Iravani [Royaume-Uni] ; Emilie Syed [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Louisa C. Johnston [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets |
| 001551 |
Angela B. Brueggemann [Royaume-Uni] ; Timothy E. A. Peto ; Derrick W. Crook ; Jay C. Butler ; Karl G. Kristinsson ; Brian G. Spratt | Temporal and Geographic Stability of the Serogroup-Specific Invasive Disease Potential of Streptococcus pneumoniae in Children |
| 001562 |
S E Hughes [Royaume-Uni] | The pathology of hypertrophic cardiomyopathy |
| 001564 |
Rina Bandopadhyay [Royaume-Uni] ; Ann E. Kingsbury [Royaume-Uni] ; Mark R. Cookson ; Andrew R. Reid ; Ian M. Evans ; Andrew D. Hope ; Alan M. Pittman ; Tammaryn Lashley ; Rosa Canet-Aviles ; David W. Miller ; Chris Mclendon ; Catherine Strand ; Andrew J. Leonard ; Patrick M. Abou-Sleiman ; Daniel G. Healy ; Hiroyashi Ariga ; Nicholas W. Wood ; Rohan De Silva ; Tamas Revesz ; John A. Hardy ; Andrew Lees (neurologue) [Royaume-Uni] | The expression of DJ‐1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease |
| 001579 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study |
| 001583 |
Iracema Leroi [Royaume-Uni, États-Unis] ; Jason Brandt [États-Unis] ; Stephen G. Reich [États-Unis] ; Constantine G. Lyketsos [États-Unis] ; Stephen Grill [États-Unis] ; Richard Thompson [États-Unis] ; Laura Marsh [États-Unis] | Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease |
| 001589 |
Francesca Cormack [Royaume-Uni] ; Dag Aarsland [Norvège] ; Clive Ballard [Royaume-Uni] ; Martin J. Tovée [Royaume-Uni] | Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia |
| 001602 |
Elanor C. Hinton [Royaume-Uni] ; John A. Parkinson [Royaume-Uni] ; Anthony J. Holland [Royaume-Uni] ; F. Sergio Arana [Royaume-Uni] ; Angela C. Roberts [Royaume-Uni] ; Adrian M. Owen [Royaume-Uni] | Neural contributions to the motivational control of appetite in humans |
| 001605 |
Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Carl Counsell [Portugal] ; Nir Giladi [Israël] ; Robert G. Holloway [États-Unis] ; Charity G. Moore [États-Unis] ; Gregor K. Wenning [Autriche] ; Melvin D. Yahr [États-Unis] ; Lisa Seidl [États-Unis] | Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease |
| 001608 |
Kathryn N. Parkinson [Royaume-Uni] ; Charlotte M. Wright [Royaume-Uni] ; Robert F. Drewett [Royaume-Uni] | Mealtime energy intake and feeding behaviour in children who fail to thrive: a population‐based case‐control study |
| 001613 |
C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie] | Levodopa in the treatment of Parkinson's disease: Current controversies |
| 001621 |
C. Panter-Brick [Royaume-Uni] ; P. G. Lunn [Royaume-Uni] ; R. Goto [Royaume-Uni] ; C. M. Wright [Royaume-Uni] | Immunostimulation and growth faltering in UK infants |
| 001629 |
M. Martinez [France] ; A. Brice [France] ; J R Vaughan [Royaume-Uni] ; A. Zimprich [Allemagne] ; M M B. Breteler [Pays-Bas] ; G. Meco [Italie] ; A. Filla [Italie] ; M J Farrer [États-Unis] ; C. Bétard [France] ; J. Hardy [États-Unis] ; G. De Michele [Italie] ; V. Bonifati [Italie] ; B. Oostra [Pays-Bas] ; T. Gasser [Allemagne] ; N W Wood [Royaume-Uni] ; A. Dürr [France] | Genome-wide scan linkage analysis for Parkinson’s disease: the European genetic study of Parkinson’s disease |
| 001637 |
Catherine Lozza [France] ; Jean-Claude Baron [France, Royaume-Uni] ; David Eidelberg [États-Unis] ; Marc J. Mentis [États-Unis] ; Maren Carbon [États-Unis] ; Rose-Marie Marié [France] | Executive processes in Parkinson's disease: FDG‐PET and network analysis |
| 001645 |
Maaike Bakker [Pays-Bas] ; Rianne A. J. Esselink [Pays-Bas] ; Marten Munneke [Pays-Bas] ; Patricia Limousin-Dowsey [Royaume-Uni] ; Hans D. Speelman [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] | Effects of stereotactic neurosurgery on postural instability and gait in Parkinson's disease |
| 001649 |
Isabella Brown [Royaume-Uni] | Does diet protect against Parkinson's disease Part 4 vitamins and minerals |
| 001650 |
Isabella Joanna Brown [Royaume-Uni] | Does diet protect against Parkinson's disease Part 2 Fat |
| 001651 |
Isabella Brown [Royaume-Uni] | Does diet protect against Parkinson's disease Part 1 vitamin E |
| 001655 |
Dominic C. Paviour [Royaume-Uni] ; Robert A. H. Surtees [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Diagnostic considerations in juvenile parkinsonism |
| 001659 |
Eilís Dowd [Royaume-Uni] ; Stephen B. Dunnett [Royaume-Uni] | Deficits in a lateralized associative learning task in dopamine‐depleted rats with functional recovery by dopamine‐rich transplants |
| 001668 |
A. W. Michell [Royaume-Uni] ; S. J. G. Lewis [Royaume-Uni] ; T. Foltynie [Royaume-Uni] ; R. A. Barker [Royaume-Uni] | Biomarkers and Parkinson's disease |
| 001673 |
Carl E. Clarke [Royaume-Uni] | A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs? |
| 001683 |
David J. Burn [Royaume-Uni] ; John T. O'Brien [Royaume-Uni] | Use of functional imaging in parkinsonism and dementia |
| 001685 |
Regina Katzenschlager [Royaume-Uni] ; Adriana Cardozo [Espagne] ; M. Rosario Avila Cobo [Espagne] ; Eduardo Tolosa [Espagne] ; Andrew Lees (neurologue) [Royaume-Uni] | Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders |
| 001696 |
V. Hugh Perry [Royaume-Uni] ; Tracey A. Newman [Royaume-Uni] ; Colm Cunningham [Royaume-Uni] | The impact of systemic infection on the progression of neurodegenerative disease |
| 001703 |
Dominique Twelves [Royaume-Uni] ; Kate S. M. Perkins [Royaume-Uni] ; Carl Counsell [Royaume-Uni] | Systematic review of incidence studies of Parkinson's disease |
| 001708 |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study |
| 001713 |
Vicky Marshall [Royaume-Uni] ; Donald Grosset [Royaume-Uni] | Role of dopamine transporter imaging in routine clinical practice |
| 001725 |
R. J. Scaramuzzi [Royaume-Uni] ; D. J. Baker [Royaume-Uni] | Possible therapeutic benefits of adenosine‐potentiating drugs in reducing age‐related degenerative disease in dogs and cats |
| 001731 |
Sofia A. Oliveira [États-Unis] ; William K. Scott [États-Unis] ; Eden R. Martin [États-Unis] ; Martha A. Nance [États-Unis] ; Ray L. Watts [États-Unis] ; Jean P. Hubble [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Matthew B. Stern [États-Unis] ; Bradley C. Hiner [États-Unis] ; William G. Ondo [États-Unis] ; Fred H. Allen Jr. [États-Unis] ; Burton L. Scott [États-Unis] ; Christopher G. Goetz [États-Unis] ; Gary W. Small [États-Unis] ; Frank Mastaglia [Australie] ; Jeffrey M. Stajich [États-Unis] ; Fengyu Zhang [États-Unis] ; Michael W. Booze [États-Unis] ; Michelle P. Winn [États-Unis] ; Lefkos T. Middleton [Royaume-Uni] ; Jonathan L. Haines [États-Unis] ; Margaret A. Pericak-Vance [États-Unis] ; Jeffery M. Vance [États-Unis] | Parkin mutations and susceptibility alleles in late‐onset Parkinson's disease |
| 001733 |
Peter Jenner [Royaume-Uni] | Oxidative stress in Parkinson's disease |
| 001734 |
Christopher Hawkes [Royaume-Uni] | Olfaction in neurodegenerative disorder |
| 001742 |
Michael Orth [Royaume-Uni] ; Sarah J. Tabrizi [Royaume-Uni] | Models of Parkinson's disease |
| 001746 |
N K Patel [Royaume-Uni] ; P. Plaha [Royaume-Uni] ; K. O Ullivan [Royaume-Uni] ; R. Mccarter [Royaume-Uni] ; P. Heywood [Royaume-Uni] ; S S Gill [Royaume-Uni] | MRI directed bilateral stimulation of the subthalamic nucleus in patients with Parkinson’s disease |
| 001753 |
David J. Brooks [Royaume-Uni] | Imaging end points for monitoring neuroprotection in Parkinson's disease |
| 001756 |
Paul K. Morrish [Royaume-Uni] | How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? |
| 001757 |
Ebba Lohmann [France] ; Magali Periquet [France] ; Vincenzo Bonifati [Italie] ; Nick W. Wood [Royaume-Uni] ; Giuseppe De Michele [Italie] ; Anne-Marie Bonnet [France] ; Valérie Fraix [France] ; Emmanuel Broussolle [France] ; Martin W. I. M. Horstink [Pays-Bas] ; Marie Vidailhet [France] ; Patrice Verpillat [France] ; Thomas Gasser [Allemagne] ; David Nicholl [Royaume-Uni] ; Hélio Teive [Brésil] ; Salmo Raskin [Brésil] ; Olivier Rascol [France] ; Alain Destée [France] ; Merle Ruberg [France] ; Francesca Gasparini [France] ; Giuseppe Meco [Italie] ; Yves Agid [France] ; Alexandra Durr [France] ; Alexis Brice [France] | How much phenotypic variation can be attributed to parkin genotype? |
| 001763 |
Thomas T. Warner [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni] | Genetic and environmental factors in the cause of Parkinson's disease |
| 001767 |
Marwan I. Hariz [Suède, Royaume-Uni] | From functional neurosurgery to “interventional” neurology: Survey of publications on thalamotomy, pallidotomy, and deep brain stimulation for Parkinson's disease from 1966 to 2001 |
| 001772 |
Mark Edwards [Royaume-Uni] ; Geoffrey Schott [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] | Episodic focal lingual dystonic spasms |
| 001774 |
D J Brooks [Royaume-Uni] ; H. Sagar [Royaume-Uni] | Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study |
| 001775 |
Paola Piccini [Royaume-Uni] ; Nicola Pavese [Royaume-Uni] ; David J. Brooks [Royaume-Uni] | Endogenous dopamine release after pharmacological challenges in Parkinson's disease |
| 001778 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Eleni Maratos [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure |
| 001783 |
Richard J. Parkinson [Royaume-Uni] ; Shahid Mian [Royaume-Uni] ; Michael C. Bishop [Royaume-Uni] ; Trevor Gray [Royaume-Uni] ; Geng Li [Royaume-Uni] ; Stephanie E. B. Mcardle [Royaume-Uni] ; Selman Ali [Royaume-Uni] ; Robert C. Rees [Royaume-Uni] | Disabled infectious single cycle herpes simplex virus (DISC‐HSV) is a candidate vector system for gene delivery/expression of GM‐CSF in human prostate cancer therapy |
| 001793 |
David J. Burn [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] | Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease |
| 001799 |
David Mckee [Royaume-Uni] ; Paul Talbot [Royaume-Uni] | Chorea as a presenting feature of variant Creutzfeldt‐Jakob disease |
| 001814 |
Willibald Gerschlager [Autriche, Royaume-Uni] ; Gerhard Bencsits [Autriche] ; Walter Pirker [Autriche] ; Bastiaan R. Bloem [Royaume-Uni, Pays-Bas] ; Susanne Asenbaum [Autriche] ; Daniella Prayer [Autriche] ; Jan C. M. Zijlmans [Royaume-Uni] ; Martha Hoffmann [Autriche] ; Thomas Brücke [Autriche] | [123I]β‐CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease |
| 001816 |
Simon G. Parkin [Royaume-Uni] ; Ralph P. Gregory [Royaume-Uni] ; Richard Scott [Royaume-Uni] ; Peter Bain [Royaume-Uni] ; Peter Silburn [Australie] ; Bruce Hall [Australie] ; Richard Boyle [Australie] ; Carole Joint [Royaume-Uni] ; Tipu Z. Aziz [Royaume-Uni] | Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: A case series of 115 patients |
| 001821 |
T. Foltynie [Royaume-Uni] ; S. Sawcer [Royaume-Uni] ; C. Brayne [Royaume-Uni] ; R A Barker [Royaume-Uni] | The genetic basis of Parkinson's disease |
| 001827 |
K R Chaudhuri [Royaume-Uni] ; S. Pal [Royaume-Uni] ; A. Dimarco [Royaume-Uni] ; C. Whately-Smith ; K. Bridgman [Royaume-Uni] ; R. Mathew [Royaume-Uni] ; F R Pezzela [Italie] ; A. Forbes [Royaume-Uni] ; B. Högl [Allemagne] ; C. Trenkwalder [Allemagne] | The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease |
| 001831 |
Katherine H. O. Deane [Royaume-Uni] ; Caroline Ellis-Hill [Royaume-Uni] ; Diana Jones [Royaume-Uni] ; Renata Whurr [Royaume-Uni] ; Yoav Ben-Shlomo [Royaume-Uni] ; E. Diane Playford [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] | Systematic review of paramedical therapies for Parkinson's disease |
| 001836 |
C. Parkinson ; W. M. Drake [Royaume-Uni] ; G. Wieringa ; A. P. Yates [Royaume-Uni] ; G. M. Besser [Royaume-Uni] ; P. J. Trainer | Serum lipoprotein changes following IGF‐I normalization using a growth hormone receptor antagonist in acromegaly |
| 001854 |
Jan Zijlmans [Royaume-Uni, Pays-Bas] ; Jan Booij [Pays-Bas] ; Jaap Valk [Pays-Bas] ; Andrew Lees (neurologue) [Royaume-Uni] ; Martin Horstink [Pays-Bas] | Posttraumatic tremor without parkinsonism in a patient with complete contralateral loss of the nigrostriatal pathway |
| 001860 |
G. Nicholson [Royaume-Uni] ; A. C. Pereira [Royaume-Uni] ; G. M. Hall [Royaume-Uni] | Parkinson’s disease and anaesthesia |
| 001891 |
Damian C. Crowther [Royaume-Uni] | Familial conformational diseases and dementias |
| 001911 |
D. J. Burn [Royaume-Uni] | Depression in Parkinson's disease |
| 001914 |
Günther Deuschl [Allemagne] ; Peter Bain [Royaume-Uni] | Deep brain stimulation for trauma: Patient selection and evaluation |
| 001920 |
Debbie Tolson [Royaume-Uni] ; Valerie Fleming [Royaume-Uni] ; Elgin Schartau [Royaume-Uni] | Coping with menstruation: understanding the needs of women with Parkinson's disease |
| 001921 |
Andrew West [États-Unis] ; Magali Periquet [France] ; Sarah Lincoln [États-Unis] ; Christoph B. Lücking [France, Allemagne] ; David Nicholl [Royaume-Uni] ; Vincenzo Bonifati ; Nina Rawal [France] ; Thomas Gasser [Allemagne] ; Ebba Lohmann [France] ; Jean-François Deleuze [France] ; Demetrius Maraganore [États-Unis] ; Allan Levey [Géorgie (pays)] ; Nick Wood [Royaume-Uni] ; Alexandra Dürr [France] ; John Hardy [États-Unis] ; Alexis Brice [France] ; Matt Farrer [États-Unis] | Complex relationship between Parkin mutations and Parkinson disease |
| 001933 |
David J. Burn [Royaume-Uni] | Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease |
| 001936 |
Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients |
| 001937 |
G C Pluck [Royaume-Uni] ; R G Brown | Apathy in Parkinson’s disease |
| 001942 |
Kevin St P. Mcnaught [États-Unis] ; P. Shashidharan [États-Unis] ; Daniel P. Perl [États-Unis] ; Peter Jenner [Royaume-Uni] ; C. Warren Olanow [États-Unis] | Aggresome‐related biogenesis of Lewy bodies |
| 001951 |
Barry J. Everitt [Royaume-Uni] ; Anthony Dickinson [Royaume-Uni] ; Trevor W. Robbins [Royaume-Uni] | The neuropsychological basis of addictive behaviour |
| 001962 |
Karen Sleeman [Royaume-Uni] ; Kyle Knox [Royaume-Uni] ; Robert George [Royaume-Uni] ; Elizabeth Miller [Royaume-Uni] ; Pauline Waight [Royaume-Uni] ; David Griffiths [Royaume-Uni] ; A. Efstratiou [Royaume-Uni] ; K. Broughton [Royaume-Uni] ; Richard T. Mayon-White [Royaume-Uni] ; E. R. Moxon [Royaume-Uni] ; D. W. Crook [Royaume-Uni] | Invasive Pneumococcal Disease in England and Wales: Vaccination Implications |
| 001968 |
Michael J. Hurley [Royaume-Uni, États-Unis] ; Deborah C. Mash [États-Unis] ; Peter Jenner [Royaume-Uni] | Dopamine D1 receptor expression in human basal ganglia and changes in Parkinson’s disease |
| 001969 |
Lori L. Jennings [Canada] ; Chunhai Hao [Canada] ; Miguel A. Cabrita [Canada] ; Mark F. Vickers [Canada] ; Stephen A. Baldwin [Royaume-Uni] ; James D. Young [Canada] ; Carol E. Cass [Canada] | Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system |
| 001988 |
Stuart Turnbull [Royaume-Uni] ; Brian J. Tabner [Royaume-Uni] ; Omar M. A El-Agnaf [Royaume-Uni] ; Susan Moore [Royaume-Uni] ; Yvonne Davies [Royaume-Uni] ; David Allsop [Royaume-Uni] | α-synuclein implicated in Parkinson’s disease catalyses the formation of hydrogen peroxide in vitro |
| 001998 |
Ernest W. Lau [Royaume-Uni] ; G. André Ng [Royaume-Uni] ; Michael J. Griffith [Royaume-Uni] | Variability in the Manifestation of Pre‐excited Atrial Fibrillation: Its Quantification, Theoretical Origin, and Diagnostic Potential |
| 001A01 |
Robert Layfield ; Andrew Alban ; R. John Mayer ; James Lowe [Royaume-Uni] | The ubiquitin protein catabolic disorders |
| 001A02 |
M C Parkinson ; S J Harland ; P. Harnden ; A. Sandison [Royaume-Uni] | The role of the histopathologist in the management of testicular germ cell tumour in adults |
| 001A09 |
Bastiaan R. Bloem [Royaume-Uni, Pays-Bas] ; Vibeke V. Valkenburg [Pays-Bas] ; Mathilde Slabbekoorn [Pays-Bas] ; Mirjam D. Willemsen [Pays-Bas] | The Multiple Tasks Test |
| 001A40 |
Elaine K. Perry [Royaume-Uni] ; Carmen M. Martin-Ruiz [Royaume-Uni] ; Jennifer A. Court [Royaume-Uni] | Nicotinic receptor subtypes in human brain related to aging and dementia |
| 001A43 |
Larry C. H. Park [États-Unis] ; David S. Albers [États-Unis] ; Hui Xu [États-Unis] ; J. Gordon Lindsay [Royaume-Uni] ; M. Flint Beal [États-Unis] ; Gary E. Gibson [États-Unis] | Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy |
| 001A44 |
M. Orth ; A. H. V. Schapira [Royaume-Uni] | Mitochondria and degenerative disorders |
| 001A48 |
Enza Maria Valente [Royaume-Uni] ; Anna Rita Bentivoglio [Italie] ; Peter H. Dixon [Royaume-Uni] ; Alessandro Ferraris [Italie] ; Tamara Ialongo [Italie] ; Marina Frontali [Italie] ; Alberto Albanese [Italie] ; Nicholas W. Wood [Royaume-Uni] | Localization of a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism, PARK6, on Human Chromosome 1p35-p36 |
| 001A51 |
J. Pearn ; C. Gardner-Thorpe [Royaume-Uni] | James Parkinson (1755–1824): A pioneer of child care |
| 001A58 |
H. Watkins [Royaume-Uni] | Hypertrophic cardiomyopathy: from molecular and genetic mechanisms to clinical management |
| 001A87 |
Patricia Dowsey-Limousin [Royaume-Uni] ; Pierre Pollak [France] | Deep brain stimulation in the treatment of Parkinson's disease: a review and update |
| 001A90 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 001A92 |
Nina Heinrichs [Royaume-Uni] ; Emily C. Hoffman [Royaume-Uni] ; Stefan G. Hofmann [Royaume-Uni, États-Unis] | Cognitive-behavioral treatment for social phobia in Parkinson's disease: A single-case study |
| 001A95 |
S. Bostantjopoulou [Grèce] ; Z. Katsarou [Grèce] ; A. Papadimitriou [Grèce] ; V. Veletza [Grèce] ; G. Hatzigeorgiou [Grèce] ; A. Lees [Royaume-Uni] | Clinical features of parkinsonian patients with the α‐synuclein (G209A) mutation |
| 001B18 |
Zhang-Yan Tong [Royaume-Uni] ; Ann E. Kingsbury [Royaume-Uni] ; Oliver J. F Foster [Royaume-Uni] | Up-regulation of tyrosine hydroxylase mRNA in a sub-population of A10 dopamine neurons in Parkinson’s disease |
| 001B19 |
Ha Rohan De Silva [Royaume-Uni] ; Naheed L. Khan [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] | The genetics of Parkinson's disease |
| 001B33 |
M. P. Decatris [Royaume-Uni] ; P. M. Wilkinson [Royaume-Uni] ; R. S. Welch [Royaume-Uni] ; M. Metzner [Royaume-Uni] ; G. R. Morgenstern [Royaume-Uni] ; M. Dougall [Royaume-Uni] | High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: An effective first-line therapy with minimal toxicity |
| 001B60 |
Maria Grazia Spillantini [Royaume-Uni] ; Michel Goedert [Royaume-Uni] | The α‐Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy |
| 001B81 |
Christian Rohlff [Royaume-Uni] | Proteomics in molecular medicine: Applications in central nervous systems disorders |
| 001C32 |
C. E Shepherd [Royaume-Uni] ; S. Bowes [Royaume-Uni] ; D. Parkinson [Royaume-Uni] ; M. Cambray-Deakin [Royaume-Uni] ; R. C. A Pearson [Royaume-Uni] | Expression of amyloid precursor protein in human astrocytes in vitro : isoform-specific increases following heat shock |
| 001C39 |
Anette Schrag [Royaume-Uni] ; Niall Quinn [Royaume-Uni] | Dyskinesias and motor fluctuations in Parkinson's disease |
| 001C42 |
Ram N Leiguarda [Argentine] ; Marcelo Merello [Argentine] ; Jorge Balej [Argentine] ; Sergio Starkstein [Argentine] ; Martín Nogues [Argentine] ; C. David Marsden [Royaume-Uni] | Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy |
| 001C44 |
Teodoro Del Ser [Espagne] ; Ian Mckeith [Royaume-Uni] ; Ravi Anand [États-Unis] ; Ana Cicin-Sain [Suisse] ; Roberto Ferrara [Italie] ; René Spiegel [Suisse] | Dementia with Lewy bodies: findings from an international multicentre study |
| 001C70 |
David S. Fedson [France] ; J. Anthony [Royaume-Uni] ; G. Scott [États-Unis] | The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known |
| 001C98 |
Federico A. Dajas-Bailador [Uruguay, Royaume-Uni] ; Marcelo Asencio [Chili] ; Carolina Bonilla [Uruguay] ; Ma. Cecilia Scorza [Uruguay] ; Carolina Echeverry [Uruguay] ; Miguel Reyes-Parada [Uruguay] ; Rodolfo Silveira [Uruguay] ; Philippe Protais [France] ; Graeme Russell [Nouvelle-Zélande] ; Bruce K. Cassels [Chili] ; Federico Dajas [Uruguay] | Dopaminergic pharmacology and antioxidant properties of pukateine, a natural product lead for the design of agents increasing dopamine neurotransmission |
| 001D02 |
A. J. Lloyd [Royaume-Uni] | Comprehension of Prosody in Parkinson's Disease |
| 001D03 |
Karen M. Rudolph [États-Unis] ; Marilyn J. Crain [Royaume-Uni] ; Alan J. Parkinson [États-Unis] ; Marilyn C. Roberts | Characterization of a Multidrug-Resistant Clone of Invasive Streptococcus pneumoniae Serotype 6B in Alaska Using Pulsed-Field Gel Electrophoresis and PspA Serotyping |
| 001D24 |
Judit Mally [Hongrie] ; T. W. Stone [Royaume-Uni] | Therapeutic and “dose‐dependent” effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson's disease |
| 001D35 |
Angela J. Lawton [Royaume-Uni] ; Graham M. Mead [Royaume-Uni] | Staging and prognostic factors in testicular cancer |
| 001D43 |
Anette Schrag [Royaume-Uni] ; Ludwig Schelosky [Allemagne] ; Udo Scholz [Allemagne] ; Werner Poewe [Autriche] | Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges |
| 001D63 |
Y. Ben-Shlomo [Royaume-Uni] ; J. Head [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Mortality in DATATOP |
| 001D65 |
C. S. Biggs [Royaume-Uni] ; M. S. Starr [Royaume-Uni] | Microdialysis study of the effects of the antiparkinsonian drug budipine on L‐DOPA‐induced release of dopamine and 5‐hydroxytryptamine by rat substantia nigra and corpus striatum |
| 001D72 |
Taylor [Royaume-Uni] ; Beerahee [Royaume-Uni] ; Citerone [États-Unis] ; Cyronak [États-Unis] ; Leigh [Royaume-Uni] ; Fitzpatrick [Royaume-Uni] ; Lopez‐Gil [Royaume-Uni] ; Vakil [Royaume-Uni] ; Burns [Royaume-Uni] ; Lennox [Royaume-Uni] | Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L‐Dopa in Patients with Parkinson's Disease |
| 001D80 |
R. G. Brown [Royaume-Uni] ; P. Limousin Dowsey [Royaume-Uni, France] ; P. Brown [Royaume-Uni] ; M. Jahanshahi [Royaume-Uni] ; Pierre Pollak [France] ; Alim-Louis Benabid [France] ; M. C. Rodriguez-Oroz [Espagne] ; J. Obeso [Espagne] ; J. C. Rothwell [Royaume-Uni] | Impact of deep brain stimulation on upper limb akinesia in Parkinson's disease |
| 001D85 |
P. Jenner [Royaume-Uni] | Genetic susceptibility and the occurrence of Parkinson's disease |
| 001E30 |
C. H. Robinson [Royaume-Uni] ; P. J. Fisher [Royaume-Uni] ; B. C. Sutton [Royaume-Uni] | Fungal biodiversity in dead leaves of fertilized plants of Dryas octopetala from a high arctic site |
| 001E46 |
Anette Schrag [Royaume-Uni] ; Yoav Ben-Shlomo [Royaume-Uni] ; Richard Brown [Royaume-Uni] ; C. David Marsden [Royaume-Uni] ; Niall Quinn [Royaume-Uni] | Young‐onset Parkinson's disease revisited—clinical features, natural history, and mortality |
| 001E48 |
Jenner [Royaume-Uni] ; C. Warren Olanow | Understanding cell death in parkinson's disease |
| 001E51 |
N J Linker [Royaume-Uni] ; A P Fitzpatrick [Royaume-Uni] | The transseptal approach for ablation of cardiac arrhythmias: experience of 104 procedures |
| 001E53 |
Brooks [Royaume-Uni] | The early diagnosis of parkinson's disease |
| 001E55 |
C. S. Biggs [Royaume-Uni] ; A. Fisher [Royaume-Uni] ; M. S. Starr [Royaume-Uni] | The antiparkinsonian drug budipine stimulates the activity of aromatic L‐amino acid decarboxylase and enhances L‐DOPA‐induced dopamine release in rat substantia nigra |
| 001E58 |
J. M Henderson [Royaume-Uni] ; S. B Dunnett [Royaume-Uni] | Targeting the subthalamic nucleus in the treatment of Parkinson’s disease |
| 001E63 |
Rascol [France] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Amos D. Korczyn [Israël] ; Warner H. Poewe [Autriche] ; Fabrizzio Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study |
| 001E69 |
Andrew G. Riedl [Royaume-Uni] ; Paul M. Watts [Royaume-Uni] ; Jenner [Royaume-Uni] ; C. David Marsden [Royaume-Uni] | P450 enzymes and Parkinson's disease: The story so far |
| 001E79 |
M. Gu [Royaume-Uni] ; J. M. Cooper [Royaume-Uni] ; J. W. Taanman [Royaume-Uni] ; Schapira [Royaume-Uni] | Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease |
| 001E87 |
Federico A. Dajas-Bailador [Uruguay, Royaume-Uni] ; Anibal Martinez-Borges [Uruguay] ; Gustavo Costa [Uruguay] ; J. Andrés Abin [Uruguay] ; Emilia Martignoni [Italie] ; Giuseppe Nappi [Italie] ; Federico Dajas [Uruguay] | Hydroxyl radical production in the substantia nigra after 6-hydroxydopamine and hypoxia-reoxygenation |
| 001E93 |
Oliver Bandmann [Royaume-Uni] ; C. David Marsden [Royaume-Uni] ; Wood [Royaume-Uni] | Genetic aspects of Parkinson's disease |
| 001F05 |
C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni] ; David Brooks [Royaume-Uni] | Dopamine agonists and neuroprotection in parkinson's disease |
| 001F13 |
Ronald K. B. Pearce [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jenner [Royaume-Uni] ; C. David Marsden [Royaume-Uni] | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset |
| 001F16 |
A. Charlett [Royaume-Uni] ; R. J. Dobbs ; A. G. Purkiss ; D. J. Wrighe ; D. W. Peterson [Royaume-Uni] ; C. Weller ; S. M. Dobbs | Cortisol is higher in parkinsonism and associated with gait deficit |
| 001F30 |
J. R. Playfer [Royaume-Uni] | Parkinson's disease. |
| 001F34 |
John Parkinson [Royaume-Uni] ; Andy Brass [Royaume-Uni] ; Giles Canova [France] ; Yves Brechet [France] | The mechanical properties of simulated collagen fibrils |
| 001F36 |
Crispin Jenkinson [Royaume-Uni] ; Ray Fitzpatrick [Royaume-Uni] ; Viv Peto [Royaume-Uni] ; Richard Greenhall [Royaume-Uni] ; Nigel Hyman [Royaume-Uni] | The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score |
| 001F38 |
O. A. Obel [Royaume-Uni] ; A. J. Camm [Royaume-Uni] | Supraventricular tachycardia |
| 001F45 |
Jim J. Hagan [Royaume-Uni] ; Derek N. Middlemiss [Royaume-Uni] ; Paul C. Sharpe [Royaume-Uni] ; George H. Poste [Royaume-Uni] | Parkinson's disease: prospects for improved drug therapy |
| 001F46 |
Jim J. Hagan [Royaume-Uni] ; Derek N. Middlemiss [Royaume-Uni] ; Paul C. Sharpe [Royaume-Uni] ; George H. Poste [Royaume-Uni] | Parkinson's disease: prospects for improved drug therapy |
| 001F52 |
C N Martyn [Royaume-Uni] | Infection in childhood and neurological diseases in adult life |
| 001F79 |
David Butler [Royaume-Uni] ; Jonathan Parkinson [Royaume-Uni] | Towards sustainable urban drainage |
| 001F82 |
E. K. Parkinson [Royaume-Uni] ; R. F. Newbold [Royaume-Uni] ; W. N. Keith [Royaume-Uni] | The genetic basis of human keratinocyte immortalisation in squatnous cell carcinoma development: The role of telomerase reactivation |
| 001F89 |
Marcia C. Smith [Royaume-Uni] ; Heiner Ellgring [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Sleep Disturbances in Parkinson's Disease Patients and Spouses |
| 001F91 |
Gregor J. Stewart [Royaume-Uni] ; Armand Savioz [Royaume-Uni] ; R. Wayne Davies [Royaume-Uni] | Sequence Analysis of 497 Mouse Brain ESTs Expressed in the Substantia Nigra |
| 002033 |
V. V. Myllyl [Finlande] ; M. Jackson [Royaume-Uni] ; J. P. Larsen [Norvège] ; H. Baas [Allemagne] | Efficacy and safety of tolcapone in levodopa‐treated Parkinson's disease patients with “wearing‐off” phenomenon: a multicentre, double‐blind, randomized, placebo‐controlled trial |
| 002037 |
Piccini [Royaume-Uni] ; P. K. Morrish [Royaume-Uni] ; N. Turjanski [Royaume-Uni] ; G. V. Sawle [Royaume-Uni] ; D. J. Burn [Royaume-Uni] ; R. A. Weeks [Royaume-Uni] ; M. H. Mark [États-Unis] ; D. M. Maraganore [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] | Dopaminergic function in familial Parkinson's disease: A clinical and 18F‐dopa positron emission tomography study |
| 002064 |
Timothy M. Cox [Royaume-Uni] ; J. Paul Schofield [Royaume-Uni] | 3 Gaucher's disease: clinical features and natural history |
| 002065 |
M R Feneley [Royaume-Uni] ; M P Young [Royaume-Uni] ; C. Chinyama [Royaume-Uni] ; R S Kirby [Royaume-Uni] ; M C Parkinson [Royaume-Uni] | Ki-67 expression in early prostate cancer and associated pathological lesions. |
| 002071 |
C. Robertson [Royaume-Uni] ; R. Hazlewood [Royaume-Uni] ; M. D. Rawson [Royaume-Uni] | The effects of Parkinson's disease on the capacity to generate information randomly |
| 002073 |
Oliver Bandmann [Royaume-Uni] ; Sue Daniel [Royaume-Uni] ; C. David Marsden [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] ; Anita E. Harding [Royaume-Uni] | The GTP-cyclohydrolase I gene in atypical Parkinsonian patients: a clinico-genetic study |
| 002075 |
R. W. F. Campbell [Royaume-Uni] | Supraventricular tachycardia |
| 002078 |
G. Parkinson [Australie] ; B. H Thorp [Royaume-Uni] ; J. Azuolas [Australie] ; S. Vaiano [Australie] | Sequential studies of endochondral ossification and serum 1,25-dihydroxycholecalciferol in broiler chickens between one and 21 days of age |
| 002080 |
Peter D. Simmonds [Royaume-Uni] ; Andrew H. S. Lee [Royaume-Uni] ; Jeffery M. Theaker [Royaume-Uni] ; Ken Tung [Royaume-Uni] ; Christopher J. Smart [Royaume-Uni] ; Graham M. Mead [Royaume-Uni] | Primary Pure Teratoma of the Testis |
| 002109 |
P. K. Morrish ; G. V. Sawle [Royaume-Uni] ; D. J. Brooks | An [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease |
| 002111 |
A. Fernandez [Espagne] ; M. L. De Ceballos [Espagne] ; S. Rose ; P. Jenner ; C. D. Marsden [Royaume-Uni] | Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease |
| 002114 |
N. A. Parkinson [Royaume-Uni] ; A. F. James [Royaume-Uni] ; B. M. Hendry [Royaume-Uni] | Actions of endothelin-1 on calcium homeostasis in Madin—Darby canine kidney tubule cells |
| 002138 |
Corcos [États-Unis, Royaume-Uni] ; Chiung-Mei Chen [Taïwan, Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] ; John Mcauley [Royaume-Uni] ; John C. Rothwell [Royaume-Uni] | Strength in Parkinson's disease: Relationshp to rate of force generation and clinical status |
| 002151 |
F. Tison [France] ; K. Wenning [Autriche] ; A. Volonte [Italie] ; R. Poewe [Autriche] ; P. Henry [France] ; P. Quinn [Royaume-Uni] | Pain in multiple system atrophy |
| 002166 |
C. Rickards [Royaume-Uni] ; F. W. J. Cody [Royaume-Uni] | Increased use of target cues during visuo‐motor tracking in Parkinson's disease |
| 002176 |
Christian Spenger [Suisse] ; K. Haque [Royaume-Uni] ; Lorenz Studer [Suisse] ; Ljudmila Evtouchenko [Suisse] ; Bendicht Wagner [Suisse] ; Beatrice Bühler [Suisse] ; Urban Lendahl [Suède] ; B. Dunnett [Royaume-Uni] ; W. Seiler [Suisse] | Fetal ventral mesencephalon of human and rat origin maintained in vitro and transplanted to 6-hydroxydopamine-lesioned rats gives rise to grafts rich in dopaminergic neurons |
| 002211 |
Waterston [Royaume-Uni] ; Graham R. Barnes [Royaume-Uni] ; Madeleine A. Grealy [Royaume-Uni] ; Sue Collins [Royaume-Uni] | Abnormalities of smooth eye and head movement control in parhson's disease |
| 002213 |
Edith Sim [Royaume-Uni] ; Lesley A. Stanley [Royaume-Uni] ; Angela Risch [Royaume-Uni] ; Peter Thygesen [Danemark] | Xenogenetics in multifactorial disease susceptibility |
| 002225 |
K. A. Flowers [Royaume-Uni] ; C. Robertson [Royaume-Uni] ; M. R. Sheridan [Royaume-Uni] | Some characteristics of word fluency in Parkinson's disease |
| 002237 |
Siew Yen Ho [Royaume-Uni] ; Robert H. Anderson [Royaume-Uni] | Morphologic aspects of pediatric arrhythmias |
| 002252 |
J. G. De Yébenes ; J. L. Sarasa ; S. E. Daniel [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Familial progressive supranuclear palsy |
| 002273 |
F. Tison ; G. K. Wenning ; S. E. Daniel [Royaume-Uni] ; N. P. Quinn | The pathophysiology of parkinsonism in multiple system atrophy |
| 002276 |
Jane E. Parkinson [Royaume-Uni] ; Christopher M. Sanderson [Royaume-Uni] ; Geoffrey L. Smith [Royaume-Uni] | The Vaccinia Virus A38L Gene Product Is a 33-kDa Integral Membrane Glycoprotein |
| 002277 |
Goetz [États-Unis] ; Glenn T. Stebbins [États-Unis] ; Teresa A. Chmura [États-Unis] ; Stanley Fahn [États-Unis] ; Harold L. Klawans [États-Unis] ; C. David Marsden [Royaume-Uni] | Teaching tape for the motor section of the unified Parkinson's disease rating scale |
| 002293 |
C. Trenkwalder [Royaume-Uni] ; W. Paulus [Royaume-Uni] ; S. Krafczyk [Royaume-Uni] ; M. Hawken [Royaume-Uni] ; W. H. Oertel [Royaume-Uni] ; Th. Brandt [Royaume-Uni] | Postural stability differentiates “lower body” from idiopathic parkinsonism |
| 002297 |
L. Williams [Royaume-Uni] ; J. Shaw [Royaume-Uni] ; James Lowe [Royaume-Uni] ; David Bates [Royaume-Uni] ; G. Ince [Royaume-Uni] | Parkinsonism in motor neuron disease: case report and literature review |
| 002335 |
Clarke [Royaume-Uni] | Does levodopa therapy delay death in Parkinson's disease? A review of the evidence |
| 002336 |
C. A. Davie [Royaume-Uni] ; G. K. Wenning [Royaume-Uni] ; G. J. Barker [Royaume-Uni] ; P. S. Tofts [Royaume-Uni] ; B. E. Kendall [Royaume-Uni] ; N. Quinn [Royaume-Uni] ; W. I. Mcdonald [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; D. H. Miller [Royaume-Uni] | Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy |
| 002345 |
I. P. Chessell [Royaume-Uni] ; P. T. Francis [Royaume-Uni] ; D. M. Bowen [Royaume-Uni] | Changes in Cortical Nicotinic Acetylcholine Receptor Numbers Following Unilateral Destruction of Pyramidal Neurones by Intrastriatal Volkensin Injection |
| 002371 |
N. S. Peters [Royaume-Uni] ; E. Rowland [Royaume-Uni] ; J. G. Bennett [Royaume-Uni] ; C. R. Green [Royaume-Uni] ; R. H. Anderson [Royaume-Uni] ; N. J. Severs [Royaume-Uni] | The Wolff-Parkinson-White syndrome: the cellular substrate for conduction in the accessory atrioventricular pathway |
| 002385 |
Rebecca Daniels [Royaume-Uni] ; Graham F. A. Harding [Royaume-Uni] ; Stephen J. Anderson [Royaume-Uni] | Effect of dopamine and acetylcholine on the visual evoked potential |
| 002395 |
Haug [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Geoffrey B. Arden [Royaume-Uni] ; Wolfgang H. Oertel [Allemagne] ; Walter Paulus [Allemagne] | Visual thresholds to low‐contrast pattern displacement, color contrast, and luminance contrast stimuli in Parkinson's disease |
| 002400 |
S. Enochs [États-Unis] ; T. Sarna [Pologne] ; L. Zecca [Italie] ; A. Riley [Royaume-Uni] ; M. Swartz [États-Unis] | The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesis |
| 002442 |
H. Ikeda [Royaume-Uni] ; G. M. Head [Royaume-Uni] ; C. J K. Ellis [Royaume-Uni] | Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson's disease and a follow up study |
| 002457 |
Jeswinder Sian ; David T. Dexter ; Andrew Lees (neurologue) [Royaume-Uni] ; Susan Daniel [Royaume-Uni] ; Yves Agid [France] ; France Javoy-Agid [France] ; Peter Jenner ; C. David Marsden [Royaume-Uni] | Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia |
| 002458 |
E. K. Perry [Royaume-Uni] ; C. M. Morris [Royaume-Uni] ; J. A. Court [Royaume-Uni] ; A. Cheng [Royaume-Uni] ; A. F. Fairbairn [Royaume-Uni] ; I. G. Mckeith [Royaume-Uni] ; D. Irving [Royaume-Uni] ; A. Brown [Royaume-Uni] ; R. H. Perry [Royaume-Uni] | Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology |
| 002464 |
P. D. Griffiths [Royaume-Uni] ; R. H. Perry [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] | A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease |
| 002475 |
Richard G. Brown [Royaume-Uni] ; Marjan Jahanshahi [Royaume-Uni] ; C. David Marsden [Royaume-Uni] | Response choice in Parkinson's disease |
| 002476 |
Jennian F. Geddes ; Andrew J. Hughes [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Susan E. Daniel [Royaume-Uni] | Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles |
| 002481 |
David J. Brooks [Royaume-Uni] | Functional imaging in relation to parkinsonian syndromes |
| 002491 |
John Joseph Downes [Royaume-Uni] ; Helen M. Sharp [Royaume-Uni] ; Brenda M. Costall [Royaume-Uni] ; Harvey J. Sagar [Royaume-Uni] ; James Howe [Royaume-Uni] | Alternating fluency in Parkinson's disease |
| 002495 |
Peter Jenner [Royaume-Uni] | Maladie de Parkinson: mécanismes physiopathologiques et effets du piribédil |
| 002503 |
D. Malcolm [Royaume-Uni] ; J. Garratt [Royaume-Uni] ; John Camm [Royaume-Uni] | The therapeutic and diagnostic cardiac electrophysiological uses of adenosine |
| 002521 |
W. Jervis [Royaume-Uni] ; R. Saatchi [Royaume-Uni] ; M. Allen [Royaume-Uni] ; R. Hudson [Royaume-Uni] ; S. Oke [Royaume-Uni] ; M. Grimsley [Royaume-Uni] | Pilot study of computerised differentiation of Huntington's disease, schizophrenic, and parkinson's disease patients using the contingent negative variation |
| 002524 |
B. Parkinson [Royaume-Uni] ; J. Shaw [Royaume-Uni] ; L. Himsworth [Royaume-Uni] ; V. Thakker [Royaume-Uni] | Parathyroid hormone gene analysis in autosomal hypoparathyroidism using an intragenic tetranucleotide (AAAT) n polymorphism |
| 002527 |
G. Kennedy [Royaume-Uni] ; Pring [Royaume-Uni] ; R. Fawcus [Royaume-Uni] | No place for motor speech acts in the assessment of dysphagia? Intelligibility and swallowing difficulties in stroke and Parkinson's disease patients |
| 002540 |
S. Markus [Royaume-Uni] ; M. Tomkins [Royaume-Uni] ; M. Stern [Royaume-Uni] | Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters |
| 002553 |
Aj Lees [Royaume-Uni] | Dopamine agonists in Parkinson's disease: a look at apomorphine |
| 002568 |
J. Till [Royaume-Uni] ; C. Wren [Royaume-Uni] | Atrial flutter in the fetus and young infant: an association with accessory connections. |
| 002577 |
J. P. Harris [Royaume-Uni] ; J. E. Calvert [Royaume-Uni] ; O. T. Phillison [Royaume-Uni] | PROCESSING OF SPATIAL CONTRAST IN PERIPHERAL VISION IN PARKINSON'S DISEASE |
| 002582 |
Klaus P. Ebmeier [Royaume-Uni] ; Douglas D. Potter [Royaume-Uni] ; Rosemary H. B. Cochrane [Royaume-Uni] ; John R. Crawford [Royaume-Uni] ; Lesley Stewart [Royaume-Uni] ; Sheila A. Calder [Royaume-Uni] ; John A. O. Besson [Royaume-Uni] ; Eric A. Salzen [Royaume-Uni] | Event related potentials, reaction time, and cognitive performance in idiopathic Parkinson's disease |
| 002595 |
V. M. Mann [Royaume-Uni] ; J. M. Cooper [Royaume-Uni] ; D. Krige [Royaume-Uni] ; S. E. Daniel [Royaume-Uni] ; A. H. V. Schapira [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | BRAIN, SKELETAL MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE |
| 002610 |
Brooks [Royaume-Uni] ; V. Ibanez [Royaume-Uni] ; G. V. Sawle [Royaume-Uni] ; E. D. Playford [Royaume-Uni] ; N. Quinn [Royaume-Uni] ; C. J. Mathias [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; R. Bannister [Royaume-Uni] ; R. S. J. Frackowiak [Royaume-Uni] | Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography |
| 002615 |
J. E. Deal [Royaume-Uni] ; M. F. Snell [Royaume-Uni] ; T. M. Barratt [Royaume-Uni] ; M. J. Dillon [Royaume-Uni] | Renovascular disease in childhood |
| 002620 |
Peter Jenner [Royaume-Uni] | Parkinson's disease: pathological mechanisms and actions of piribedil |
| 002624 |
Jenner [Royaume-Uni] ; D. T. Dexter [Royaume-Uni] ; J. Sian [Royaume-Uni] ; A. H. V. Schapira [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease |
| 002649 |
Dexter [Royaume-Uni] ; Peter Jenner [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni] ; C. David Marsden [Royaume-Uni] | Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia |
| 002666 |
Kenneth C. Mccullough [Royaume-Uni, Suisse] ; Timothy U. Obi [Royaume-Uni, Nigeria] ; Hooshmand Shesberadaran [Royaume-Uni, Suède] | Identification of epitope(s) on the internal virion proteins of rinderpest virus which are absent from peste des petits ruminants virus |
| 002672 |
James A. Cooper ; Harvey J. Sagar ; Nigel Jordan ; Norman S. Harvey [Royaume-Uni] ; Edith V. Sullivan [États-Unis] | COGNITIVE IMPAIRMENT IN EARLY, UNTREATED PARKINSON'S DISEASE AND ITS RELATIONSHIP TO MOTOR DISABILITY |
| 002718 |
S. Compston [Royaume-Uni] | Book review — James Parkinson: his life and times by A. D. Morris |
| 002752 |
J. A. Johnson [Royaume-Uni] ; T. R. Pring [Royaume-Uni] | Speech therapy and Parkinson's disease: A review and further data |
| 002760 |
K. P. Ebmeier [Royaume-Uni] ; S. A. Calder [Royaume-Uni] ; J. R. Crawford [Royaume-Uni] ; L. Stewart [Royaume-Uni] ; J. A. O. Besson [Royaume-Uni] ; W. J. Mutch [Royaume-Uni] | Parkinson's disease in Aberdeen: survival after 3.5 years |
| 002761 |
Thomas K. Pitcairn [Royaume-Uni] ; Susan Clemie [Royaume-Uni] ; John M. Gray [Royaume-Uni] ; Brian Pentland [Royaume-Uni] | Non‐verbal cues in the self‐presentation of Parkinsonian patients |
| 002773 |
Thomas K. Pitcairn [Royaume-Uni] ; Susan Clemie [Royaume-Uni] ; John M. Gray [Royaume-Uni] ; Brian Pentland [Royaume-Uni] | Impressions of parkinsonian patients from their recorded voices |
| 002785 |
K. Perry [Royaume-Uni] ; J. Smith [Royaume-Uni] ; A. Court [Royaume-Uni] ; H. Perry [Royaume-Uni] | Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types |
| 002789 |
C. R. V. Tomson ; S. M. Channon [Royaume-Uni] ; M. K. Ward ; M. F. Laker [Royaume-Uni] | Ascorbate‐induced hyperoxalaemia has no significant effect on lactate generation or erythrocyte 2,3, diphosphoglycerate in dialysis patients |
| 002791 |
J M Pearce [Royaume-Uni] | Aspects of the history of Parkinson's disease. |
| 002792 |
W R Gibb [Royaume-Uni] ; C Q Mountjoy [Royaume-Uni] ; D M Mann [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | A pathological study of the association between Lewy body disease and Alzheimer's disease. |
| 002798 |
A. G. M. Canavan [Royaume-Uni] ; R. E. Passingham [Royaume-Uni] ; C. D. Marsden ; N. Quinn [Royaume-Uni] ; M. Wyke ; C. E. Polkey [Royaume-Uni] | The performance on learning tasks of patients in the early stages of Parkinson's disease |
| 002799 |
J. P. R. Dick [Royaume-Uni] ; J. C. Rothwell [Royaume-Uni] ; B. L. Day [Royaume-Uni] ; R. Cantello [Royaume-Uni] ; O. Buruma [Royaume-Uni] ; M. Gioux [Royaume-Uni] ; R. Benecke [Royaume-Uni] ; A. Berardelli [Royaume-Uni] ; P. D. Thompson [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | THE BEREITSCHAFTSPOTENTIAL IS ABNORMAL IN PARKINSON'S DISEASE |
| 002801 |
C. R. V. Tomson [Royaume-Uni] ; S. M. Channon [Royaume-Uni] ; M. K. Ward [Royaume-Uni] ; M. F. Laker [Royaume-Uni] | Plasma Oxalate Concentration, Oxalate Clearance and Cardiac Function in Patients Receiving Haemodialysis |
| 002806 |
A. R. Crossman [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; S. Boyce [Royaume-Uni] ; M. R. Luquin [Royaume-Uni] ; M. A. Sambrook [Royaume-Uni] | Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey |
| 002818 |
W. R. G. Gibb ; Andrew Lees (neurologue) [Royaume-Uni] | THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE |
| 002849 |
O. Isacson [Royaume-Uni] ; D. Riche [France] ; P. Hantraye [France] ; V. Sofroniew [Royaume-Uni] ; M. Maziere [France] | A primate model of Huntington's disease: cross-species implantation of striatal precursor cells to the excitotoxically lesioned baboon caudate-putamen |
| 002850 |
E. Rowland [Royaume-Uni] ; K. Robinson [Royaume-Uni] ; S. Edmondson [Royaume-Uni] ; D M Krikler [Royaume-Uni] ; H H Bentall [Royaume-Uni] | Cryoablation of the accessory pathway in Wolff-Parkinson-White syndrome: initial results and long term follow up. |
| 002851 |
A. M. Gotham [Royaume-Uni] ; R. G. Brown [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | ‘FRONTAL’ COGNITIVE FUNCTION IN PATIENTS WITH PARKINSON'S DISEASE ‘ON’AND ‘OFF’ LEVODOPA |
| 002860 |
R. G. Brown [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] | INTERNAL VERSUS EXTERNAL CUES AND THE CONTROL OF ATTENTION IN PARKINSON'S DISEASE |
| 002877 |
E. Sofic [Allemagne] ; P. Riederer [Allemagne] ; H. Heinsen [Allemagne] ; H. Beckmann [Allemagne] ; P. Reynolds [Royaume-Uni] ; G. Hebenstreit [Autriche] ; H. Youdim [Israël] | Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain |
| 002878 |
A. P. Weetman [Royaume-Uni] ; A. K. So [Royaume-Uni] ; C. A. Warner [Royaume-Uni] ; L. Foroni [Royaume-Uni] ; P. Fells [Royaume-Uni] ; B. Shine [Royaume-Uni] | IMMUNOGENETICS OF GRAVES' OPHTHALMOPATHY |
| 002881 |
Brian Parkinson [Royaume-Uni] ; Lynne Colgan [Royaume-Uni] | False autonomic feedback: Effects of attention to feedback on ratings of pleasant and unpleasant target stimuli |
| 002885 |
Poewe [Autriche] ; Andrew Lees (neurologue) [Royaume-Uni] ; G. M. Stern [Royaume-Uni] | Dystonia in parkinson's disease: Clinical and pharmacological features |
| 002888 |
N. Cooper [Royaume-Uni] ; F. Clayton [Royaume-Uni] | DNA polymorphism and the study of disease associations |
| 002896 |
J. P. R Dick [Royaume-Uni] ; R. Cantello [Royaume-Uni] ; O. Buruma [Royaume-Uni] ; M. Gioux [Royaume-Uni] ; R. Benecke [Royaume-Uni] ; B. L Day [Royaume-Uni] ; J. C Rothwell [Royaume-Uni] ; P. D Thompson [Royaume-Uni] ; C. D Marsden [Royaume-Uni] | The Bereitschaftspotential, l-DOPA and parkinson's disease |
| 002905 |
K. C. Mccullough [Royaume-Uni, Suisse] ; J. R. Crowther [Royaume-Uni] ; W. C. Carpenter [Royaume-Uni] ; E. Brocchi [Italie] ; L. Capucci [Italie] ; F. De Simone [Italie] ; Q. Xie [Royaume-Uni] ; D. Mccahon [Royaume-Uni] | Epitopes on foot-and-mouth disease virus particles I. Topology |
| 002908 |
D. Rogers ; Andrew Lees (neurologue) [Royaume-Uni] ; Eileen Smith ; M. Trimble ; G. M. Stern | BRADYPHRENIA IN PARKINSON'S DISEASE AND PSYCHOMOTOR RETARDATION IN DEPRESSIVE ILLNESS |
| 002910 |
Niall Quinn [Royaume-Uni] ; Peter Critchley [Royaume-Uni] ; Marsden [Royaume-Uni] | Young onset Parkinson's disease |
| 002915 |
G. Gibb [Royaume-Uni] ; J. Lees [Royaume-Uni] | The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome |
| 002943 |
R. G Brown [Royaume-Uni] ; C. D Marsden [Royaume-Uni] | VISUOSPATIAL FUNCTION IN PARKINSON'S DISEASE |
| 002950 |
Andrew Lees (neurologue) [Royaume-Uni] | L-Dopa Treatment and Parkinson's Disease |
| 002956 |
Niall P. Quinn [Royaume-Uni] ; Martin N. Rossor [Royaume-Uni] ; C David Marsden [Royaume-Uni] | DEMENTIA AND PARKINSON'S DISEASE — PATHHOLOGICAL AND NEUROCHEMICAL CONSIDERATIONS |
| 002971 |
Brian Parkinson [Royaume-Uni] ; R. Manstead [Royaume-Uni] | False autonomic feedback: Effects of attention to feedback on ratings of erotic stimuli |
| 002988 |
M. A. Stanley ; N. S. Crowcroft ; J. P. Quigley ; E. K. Parkinson [Royaume-Uni] | Responses of human cervical keratinocytes in vitro to tumour promoters and diethylstilboestrol |
| 002A09 |
R. L. G. Sutcliffe [Royaume-Uni] ; R. Prior [Royaume-Uni] ; B. Mawby [Royaume-Uni] ; W. J. Mcquillan [Royaume-Uni] | Parkinson's disease in the district of the Northampton Health Authority, United Kingdom. A study of prevalence and disability |
| 002A30 |
R. S. F. Schilling [Royaume-Uni] | More Effective Prevention in Occupational Health Practice? |
| 002A40 |
K. C. Mccullough [Royaume-Uni] ; D. Parkinson [Royaume-Uni] | The standardization of a ‘spot-test’ ELISA for the rapid screening of sera and hybridoma cell products II. The determination of binding capacity, binding ratio and coefficient of variation of different ELISA plates in sandwich and indirect ELISA |
| 002A41 |
K. C. Mccullough [Royaume-Uni] ; D. Parkinson [Royaume-Uni] | The standardization of a ‘spot-test’ ELISA for the rapid screening of sera and hybridoma cell products I. The determination of the optimum buffering system |
| 002A69 |
Andrew Lees (neurologue) [Royaume-Uni] ; Eileen Smith | COGNITIVE DEFICITS IN THE EARLY STAGES OF PARKINSON'S DISEASE |
| 002B15 |
A. E. Lang [Royaume-Uni, Canada] ; N. Quinn [Royaume-Uni] ; S. Brincat [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; Parkes [Royaume-Uni] | Pergolide in late‐stage Parkinson disease |
| 002B20 |
A. C. Bird [Royaume-Uni] | INVESTIGATION OF RETINITIS PIGMENTOSA |
| 002B27 |
A. E. Lang [Royaume-Uni, Canada] ; Marsden [Royaume-Uni] ; J. A. Obeso [Royaume-Uni] ; J. D. Parkes [Royaume-Uni] | Alcohol and Parkinson disease |
| 002B41 |
C. J. Fowler [Irlande (pays)] ; L. Oreland [Suède] ; B. A. Callingham [Royaume-Uni] | The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J‐508: their properties and applications |
| 002B48 |
J. D. Parkes ; M. Schachter ; C. D. Marsden ; B. Smith [Royaume-Uni] ; A. Wilson [Royaume-Uni] | Lisuride in parkinsonism |
| 002B63 |
L. H. Opie [Royaume-Uni, Afrique du Sud] | IV. ANTIARRHYTHMIC AGENTS |
| 002B68 |
David Parkinson [Royaume-Uni] ; Geoffrey A. Lyles [Royaume-Uni] ; Barbara J. Browne [Royaume-Uni] ; Brian A. Callingham [Royaume-Uni] | Some factors influencing the metabolism of benzylamine by type A and B monoamine oxidase in rat heart and liver |
| 002C16 |
T. D. Reisine [États-Unis] ; J. Z. Fields [États-Unis] ; H. I. Yamamura [États-Unis] ; E. D. Bird [Royaume-Uni] ; E. Spokes [Royaume-Uni] ; P. S. Schreiner [États-Unis] ; S. J. Enna [États-Unis] | Neurotransmitter receptor alterations in Parkinson's disease |
| 002C20 |
M. Coward [Royaume-Uni] ; S. Doggett [Royaume-Uni] | The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954 |
| 002C24 |
I. Bartram [Royaume-Uni] | Radiology in the current assessment of ulcerative colitis |
| 002C34 |
K. C. Simpkins [Royaume-Uni] | Aphthoid ulcers in Crohn's colitis |
| 002C45 |
R. S. Mcilwaine [Royaume-Uni] ; J. P. Malone [Royaume-Uni] | Effects of chloropicrin soil treatment on the microflora of soil and ryegrass roots and on ryegrass yield |
| 002C70 |
Hugh Trowell [Ouganda, Royaume-Uni] ; Neil Painter [Ouganda, Royaume-Uni] ; Denis Burkitt [Ouganda, Royaume-Uni] | Aspects of the epidemiology of diverticular disease and ischemic heart disease |
| 002C78 |
C. R. Whitfield [Royaume-Uni] | Measurement of pulmonary surfactant in amniotic fluid in the assessment of fetal lung development and of the risk of neonatal respiratory distress |
| 002C90 |
Alec Coppen [Royaume-Uni] ; Maryse Metcalfe [Royaume-Uni] ; J. D. Carroll [Royaume-Uni] ; J. G. L. Morris [Royaume-Uni] | LEVODOPA AND L-TRYPTOPHAN THERAPY IN PARKINSONISM |
| 002D37 |
J. W. Warburton [Royaume-Uni] | Memory disturbance and the Parkinson syndrome |
| 002D49 |
John Laidlaw [Royaume-Uni] ; J. Catling [Royaume-Uni] | An E.E.G. assessment of encephalopathy in Parkinsonism |
| 002D62 |
Maxwell Telling [Royaume-Uni] ; Geoffreyh. Wooler [Royaume-Uni] | EXCISION OF CARDIAC ANEURYSM |
| 002D76 |
George J. Cunningham [Royaume-Uni] ; Thomas Parkinson [Royaume-Uni] | Diffuse Cystic Lungs of Granulomatous Origin |
